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Heme is an essential cofactor involved in various biological processes including 
oxygen transport, xenobiotic detoxification, oxidative metabolism, gas sensing, 
circadian rhythm, signal transduction, microRNA processing and thyroid hormone 
synthesis. Heme is also an essential nutrient for parasites and is the major dietary iron 
source for humans. Despite our extensive understanding of the mechanisms of heme 
synthesis and degradation in eukaryotes, little is known as to how heme is transported 
and trafficked in eukaryotes. Recently, CeHRG-1 and CeHRG-4 were identified as 
the first bona fide heme importers/transporters using the heme auxotroph, 
Caenorhabditis elegans. To gain mechanistic insights into the heme transport 
function of HRG-1-related proteins, we conducted a structure-function analysis of 
CeHRG-1 and CeHRG-4 by exploiting yeast mutants that are genetically defective in 
  
heme synthesis.  Our studies reveal that HRG-1-related proteins transport heme 
across membranes through the coordinated actions of strategically placed amino acids 
that are topologically conserved in both, the worm and human proteins. To further 
dissect the functional elements that dictate their intracellular localization, we 
generated a series of chimeras by swapping the amino and carboxy terminal segments 
of CeHRG-1 and CeHRG-4. Our analysis in yeast and mammalian cells demonstrate 
that the C-terminal domains are essential for membrane localization of the protein, 
while the N-terminal domains are important for proper function, and plausibly 
multimerization of HRG-1-related proteins.  Currently, there are no pharmacological 
means to aid in the study of the cellular and physiological roles of eukaryotic heme 
transporters. We, for the first time, developed and executed a high-throughput screen 
of 233,360 compounds, to identify potential antagonists of HRG-1-related proteins by 
utilizing parasite heme transporters as the primary screening bait. Subsequent study in 
parasites will provide novel drug candidates against helminths that infect humans, 
livestock, and plants, as well as against genetic disorders of heme and iron 
metabolism in humans.  Taken together, results from our studies will significantly 
advance novel functional and therapeutic insights into HRG-1 mediated heme 
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Chapter 1: Introduction 
 Iron deficiency is a major diet-related health problem that affects 60 to 80% 
percent of the world’s population. In spite of the fact that iron is one of the Earth’s 
most abundant metals, nearly two billion people are affected by iron-deficiency 
anemia. In developing countries, nutritional iron deficiency is often accompanied and 
exacerbated by malaria and hookworm infections. The malaria parasite, Plasmodium 
falciparum, causes anemia by destroying parasitized red blood cells, and sequestering 
iron to reduce host iron absorption. Hookworms cause anemia as they feed on blood 
from lacerated capillaries in the intestinal mucosa [1]. As a result, iron supplements 
should be considered in therapeutic treatments for both malaria and hookworm 
infections [2,3]. Two main factors contribute to the high incidence of iron deficiency 
anemia. At the pH of duodenum, Fe2+ oxidizes to Fe3+ and then precipitates to form 
ferric hydroxide or hydroxyl-iron dimers, which are absorbed poorly by the small 
intestine. In addition, plant compounds such as tannins and phytates can chelate free 
iron, therefore prevent iron absorption [4].  
By contrast, heme (iron-protoporphyrin IX) is a more readily bioavailable iron 
source and contributes to two-third of body iron, even though heme constitutes only a 
third of total dietary iron [5]. This is because the plant compounds that interfere with 
iron absorption do not influence heme uptake and heme is soluble in the alkaline pH 
of the small intestine [6]. Heme is an essential cofactor for many proteins involved in 
various biological processes including oxygen transport, xenobiotic detoxification, 




processing and thyroid hormone synthesis [7,8,9,10,11,12]. Heme synthesis occurs 
via a highly conserved, eight-step pathway in most prokaryotes and eukaryotes. 
Cellular heme levels are tightly controlled by maintaining a balance between heme 
biosynthesis and heme degradation by the enzyme heme oxygenase. Additionally, 
intracellular and intercellular heme trafficking play a role in maintaining heme 
homeostasis. For example, a huge amount of heme is required during erythropoiesis, 
which may not be satisfied by the cell’s internal capacity for heme synthesis but may 
require mobilization of heme from stored compartments. Another possibility is that 
heme may be redistributed from “heme-rich” tissues to tissues which have a large, 
transient requirement for heme during embryonic development. Although heme 
biosynthesis and its regulation have been well characterized, the mechanisms for 
heme transport in eukaryotes remain poorly understood. In addition, Trypanosomatid 
and helminth parasites lack part or all of the enzymes of the heme synthesis pathway, 
and acquire heme exogenously to sustain their survival [13,14,15]. Understanding 
heme transport will open a novel therapeutic way for anthelminthic drug 
development. 
 
Heme homeostasis and erythropoiesis 
Heme biosynthesis and regulation 
Heme is synthesized in most eukaryotic cells through a series of eight highly 
conserved enzymatic steps (Fig. 1.1). In the human bone marrow, nearly 85% of 




Figure 1.1. The eukaryotic heme biosynthesis pathway. The first step of heme 
synthesis occurs in the mitochondrial matrix with the condensation of succinyl-CoA 
and glycine by ALAS to generate ALA. The mechanism of ALA transport across the 
outer membrane (OM) into the cytoplasm is unknown. ALA is converted to CPgenIII 
by four enzymatic reactions. CPgenIII is then transported back into the mitochondrial 
intermembrane space (IMS), possibly via ABCB6, where it is converted to PPgenIX 
by CPOX. The conversion of PPgenIX to PPIX is catalyzed by PPOX. The last step is 
the addition of Fe+2 by FECH to generate heme. The transporter responsible for heme 
transport across the OM into the cytoplasm remains unidentified. (Adapted from 










Mutations in heme synthesis enzymes as well as porphyrin transporters have been 
associated with several variants of anemias and porphyrias [17]. 
The first step in the heme biosynthetic pathway is the condensation of glycine 
and succinyl CoA and to form 5-aminolevulinic acid (ALA). This step is catalyzed by 
ALA synthase (ALAS). In most vertebrates, there are two isoforms of ALAS, ALAS1 
and ALAS2 [18,19,20]. ALAS1 (or ALAS–N) is expressed in all tissues, while 
ALAS2 (or ALAS–E) is expressed only in erythroid cells [21,22]. Mutations in 
ALAS2 have been shown to cause X-linked sideroblastic anemia (XLSA) due to 
reduced mitochondrial enzymatic activity [23]. ALA synthesis occurs in the matrix of 
mitochondria. Thus glycine must be transported from the cytosol into mitochondria. It 
has been recently reported that SLC25A38 is a mitochondrial glycine importer 
localized to the mitochondrial inner membrane. Mutations in SLC25A38 cause 
nonsyndromic congenital sideroblastic anemia in humans, whereas deficiencies in the 
SLC25A38 homolog, YDL119c, reduce ALA levels in yeast [24]. It has also been 
proposed that single-nucleotide polymorphisms of ALAS2 may have a modulatory 
effect on erythropoietic diseases [25].   
ALA is transported out of mitochondria for the subsequent four steps of heme 
biosynthesis which occur in the cytosol. ALA dehydratase (ALAD) converts two 
molecules of ALA to porphobilinogen (PBG), an intermediate with a single pyrrole 
group. Porphobilinogen deaminase (PBGD) catalyzes the conversion of four 
molecules of PBG to an unstable polymer hydroxymethylbilane; uroporphyrinogen 
synthase (UROS) converts hydroxymethylbilane to uroporphyrinogen III 




uroporphyrinogen decarboxylase (UROD) to form coproporphyrinogen III (CPgenIII). 
CPgenIII is possibly transported through an ATP-binding cassette (ABC) protein, 
ABCB6, into mitochondria [26,27]. ABCB6 localizes to the mitochondrial outer 
membrane. Although the expression profile of ABCB6 mimics that of other heme 
biogenesis genes, it has not been reported that ABCB6 function is associated with 
blood defects in mice or humans [28]. Indeed, recent studies have shown that ABCB6 
is dispensable for erythropoiesis and instead of mitochondria, it is localized in the 
endosomal/lysosomal compartment and in the plasma membrane of mature 
erythrocytes [29,30]. 
CPgenIII is converted by coproporphyrinogen oxidase (CPOX), an enzyme 
found in the mitochondrial intermembrane space, to form protoporphyrinogen IX 
(PPgenIX). The second to last step of the pathway is the oxidation of PPgenIX by 
protoporphyrinogen oxidase (PPOX) to form protoporphyrin IX (PPIX). In the final 
step, ferrochelatase (FECH) catalyzes the insertion of ferrous iron into the 
protoporphyrin IX (PPIX) ring to form protoheme or heme b. Heme b is modified at 
the C-2 and C-8 positions to form heme a, the form of heme that is found in 
cytochrome oxidases [31]. These modifications occur in two steps involving heme o 
synthase and heme a synthase. Heme c is found in cytochromes c1 and cytochrome c. 
Heme c differs from heme b in that heme c binds proteins covalently through the two 
vinyl side chains [32]. The biosynthesis of heme, thus, also relies on the intracellular 
availability of iron. Ferrous iron enters the mitochondrial intermembrane space and is 




in erythroblasts [33,34] and mitoferrin2 (MFRN2) in proerythroblasts and 
nonerythroid cells [34,35,36]. 
Cells of different tissues have different heme requirements, and the pathway 
must be regulated accordingly. Erythroid precursors need to produce a greater amount 
of heme than other tissues for insertion into hemoglobin. In contrast to other cell 
types, heme produced in erythroid tissue is used to deliver oxygen to all tissues of the 
body. Therefore, erythroid precursors produce heme as long as iron is available. 
Upregulation of heme synthesis in erythrocytes at the transcriptional level is mainly 
achieved via erythroid-specific transcription factors. Differential transcriptional 
regulation is found in the first enzyme of the heme synthesis pathway, ALAS. 
ALAS1 is expressed ubiquitously, and is downregulated by heme [37,38,39]. The 
erythroid-specific isoform ALAS2, however, has a different regulation pattern than 
ALAS1. At the transcriptional level, ALAS2 is upregulated during erythropoiesis 
through the binding of erythroid-specific factors, such as GATA-1 and NF-E1, to 
their target sequences [37]. At the post-transcriptional level, ALAS2 is downregulated 
under low iron conditions by the IRP/IRE system [18]. Thus, erythroid levels of 
ALAS2 are directly linked to iron availability. This post-transcriptional regulation of 
ALAS2 allows cells to quickly adjust the heme synthesis pathway according to iron 
levels.  
ALAD encodes the second enzyme in the heme synthesis pathway, and 
consists of eleven coding exons and two non-coding exons (1A and 1B). Differential 
regulation is achieved by utilizing two different promoters. The erythroid-specific 




Although the transcripts differ to allow for upregulation specifically in erythropoietic 
tissue, the resulting proteins are identical because the translational start site for both 
transcripts is in exon 2 [40].  The third and fourth genes in the pathway, PBGD and 
UROS, are transcriptionally regulated in a manner similar to ALAD by a 
housekeeping promoter in all cell types and an erythroid-specific promoter in 
erythroid tissue. Unlike ALAD, alternative splicing of PBGD leads to proteins that 
differ in the N-terminus [41,42,43]. Transcription of the next gene in the pathway, 
UROD, is also increased in erythroid tissues. However, the mechanism of regulation 
remains unclear, since it does not have an erythroid-specific promoter [44]. CPOX is 
the sixth gene in the heme synthesis pathway. The promoter of CPOX has a SP1-like 
element, a GATA-1 site, and a novel regulatory element, CPRE, which binds to 
erythroid-specific transcription factors like Klp1, to regulate transcription [45]. 
Interestingly, the CPRE element is also found in the human β-globin promoter, 
another gene that is upregulated in erythroid tissue [46]. The second to last gene, 
PPOX, is upregulated in erythroid cells due to two GATA sites contained within the 
first exon [47].  
The final gene in the pathway, ferrochelatase (FECH), achieves differential 
expression in a manner similar to CPOX and PPOX. There is a single promoter which 
contains binding sites for SP1, NF-E2, and GATA-1. In K562 cells, a 
erythroleukemia cell line, the SP1 binding site was sufficient to drive erythroid 
expression of FECH [48]. It has also been shown that a point mutation in one of the 
SP1 binding sites disrupts proper transcription of the FECH mRNA and leads to 




binding site is necessary for both basal expression in pluripotent cells and erythroid-
specific upregulation. The same study also demonstrated that the GATA-1 binding 
element acts as a repressor in pluripotent cells, but an enhancer during erythropoietic 
development [50]. FECH expression is also upregulated by iron sufficiency and 
hypoxia. The iron dependent regulation of FECH is due to an iron-sulfur cluster in its 
C-terminus [51]. It is induced by hypoxia due to two hypoxia inducible factor (HIF) 
binding sites in its promoter [52]. It is not surprising that the synthesis of heme is 





Although dietary uptake of heme constitutes a major source of iron, it has 
been difficult to study intercellular heme transport in eukaryotes due to its intricate 
link with heme biosynthesis [53]. Heme carrier protein 1 (HCP1/ SLC46A1) is a 
membrane protein expressed by enterocytes in the duodenum implicated in the 
absorption of heme in the intestine [54]. Functional studies in Xenopus oocytes 
expressing HCP1, revealed a 2-3 fold increase in heme uptake. Subsequent studies, 
however, have shown that SLC46A1 is in fact a folate/proton symporter and was 
renamed as the Proton Coupled Folate Transporter (PCFT/HCP-1) [55]. Loss-of-




Figure 1.2. A schematic description of intracellular heme trafficking. Heme can 
be exported out of the cell or imported into the cell. The cell-surface FLVCR and the 
ABC transporter ABCG2 have been implicated in heme export in erythroid cells, 
whereas HRG-1 was identified as a heme importer. Question marks represent the 
presumptive heme trafficking pathways. COX, cytochrome c oxidase; Cytb5, 












malabsorption with no apparent defects in erythropoiesis. RNA interference assays of 
HCP1 in CaCo-2 cells reduced pH-dependent folate uptake by 60-80%. Folate 
transport by this protein was at least an order of magnitude higher than that observed 
with heme, suggesting that folate might be the physiological ligand for HCP-1. 
Interestingly, human patients with hereditary folate malabsorption carry a missense 
mutation in HCP1 that leads to the formation of a non-functional protein. HCP1-/- 
erythroblasts are more prone to apoptosis and fail to differentiate [56].  Currently, it is 
unclear whether the erythropoietic defects observed in HCP1-/- animals are the direct 
result of inadequate dietary heme uptake or secondary to folic acid deficiency that per 
se is a major risk factor for developing megaloblastic anemia in humans [57].  
Rao et al have demonstrated the roundworm C. elegans to be an excellent 
model for heme trafficking studies because it is a heme auxotroph that still requires 
intestinal uptake of dietary heme and subsequent dissemination throughout the 
organism for viability [15]. Genomic screens in C. elegans identified CeHRG-1 and 
CeHRG-4 as the first eukaryotic heme importers [58]. CeHRG-1 has orthologs in 
vertebrates, while CeHRG-4 is worm-specific. Transient knockdown of hrg-1 in 
zebrafish resulted in hydrocephalus, yolk tube malformations and, most strikingly, 
anemia. Worm HRG-1 fully rescued all phenotypes observed due to knockdown of 
hrg-1 in zebrafish [58]. The phenotypes resulting from knockdown of zebrafish hrg-1 
were restricted specifically to the erythroid lineage and did not impact other 
hematopoietic lineages. Additionally, significant heme-induced inward currents were 




the human homolog, hHRG-1, indicating heme-dependent transport across 
membranes [58]. 
Human HRG-1 mRNA was abundant in the brain, kidney, heart and skeletal 
muscle and in cell lines derived from duodenum, kidney, bone marrow and brain [58]. 
hHRG-1 localized to acidic endosomal and lysosomal organelles in HEK293 cells, 
and its affinity for heme decrease with increasing pH. Additionally, tyrosine (YxxxØ) 
and acidic-dileucine (DxxIL) based sorting motifs were found in the C-terminus of 
both C. elegans and human HRG-1 [58]. Yanatori and colleagues recently reported 
hHRG-1 localized to the plasma membrane and lysosomes in non-polarized HEp2 
cells. In polarized MDCK cells, hHRG-1 was located to the basolateral membrane 
and a cytosolic organelle just under the apical membrane [59].  A recent study 
showed that hHRG-1 interacted with the c subunit of the vacuolar proton ATPase (V-
ATPase) pump and enhanced endosomal acidification [60]. Together these suggest 
hHRG-1 plays a role in the transport of heme from the exoplasmic space or lumen of 
acidic endosome–lysosome compartments into the cytoplasm.  
Recent expression analyses performed in C. elegans has identified two 
additional genes, MRP-5 and F22B5.4, that are required for proper intestinal heme 
transport in adult worms [61]. Both genes encode membrane proteins and may play a 
role in heme transport in C. elegans although their roles in vertebrate heme 






To date, two different plasma membrane exporters that recognize heme as a 
substrate have been identified. In mammals, FLVCR1 (feline leukemia virus, 
subgroup C receptor 1) was recently shown to be a cell surface heme exporter and 
FLVCR1-/- mice developed severe anemia, which was postulated to be due to the 
inability of macrophages and erythroblasts to export heme [62,63]. Mutations in 
FLVCR1 cause posterior column ataxia and retinitis pigmentosa due to dysregulation 
of heme homeostasis in a subpopulation of neurons in the retina and posterior 
columns of the spinal cord [64]. Interestingly, Tolosano et al  have shown that in 
addition to full length FLVCR1 (FLVCR1a), there is another isoform, FLVCR1b, 
which is a shortened protein localized in mitochondria. Targeted deletion of 
FLVCR1a resulted in skeletal defects and vascular abnormalities but did not affect 
erythropoiesis, whereas knockdown of FLVCR1b impaired erythroid differentiation 
in vitro. Their results suggested FLVCR1b is a mitochondrial heme exporter. The 
physiological function of FLVCR1a remains unknown. A closely related homolog, 
FLVCR2, is reported to be a membrane-bound heme importer and may play a role in 
the extracellular endocytosis of heme. Knockdown of FLVCR2 in human cells 
resulted in a significant decline in import of the fluorescent heme analog, zinc 
mesoporphyrin. Quantitative real-time PCR analysis found that FLVCR2 transcripts 
can be detected in a wide range of human tissues including the fetal liver [65]. Recent 
studies have associated FLVCR2 with Fowler syndrome, a vascular disorder of the 





A second protein, breast cancer resistance protein (BCRP, also known as 
ATP-binding cassette transporter G2 or ABCG2) has been implicated in heme export 
in humans. Similar to ABCB6, ABCG2 is a member of the ATP-binding cassette 
transporter family that is expressed by hematopoietic progenitors [68]. Recent 
evidence indicates that ABCG2 binds directly to heme via an extracellular domain 
and delivers heme to extracellular chaperone proteins such as albumin [69]. In 
particular, the extracellular loop 3 of ABCG2 (ECL3) constitutes a porphyrin-binding 
domain, which strongly interacts with heme, hemin, and PPIX. Currently, the 
importance of ABCG2 in normal blood development is unknown. The expression 
level of ABCG2 is particularly high in the early stages of hematopoiesis, whereas that 
of FLVCR1 is high during erythropoiesis [68]. Thus, it has been hypothesized that 
these two heme exporters might have different roles or expression patterns depending 
on physiological conditions.  
 
Heme intercellular trafficking 
To date, several intercellular heme transport proteins have been identified in 
vertebrates; however, none of them directly contributes to erythropoiesis. Free, 
circulating heme binds to and is sequestered by a plasma protein, hemopexin, which 
delivers its bound heme to various cells types where it is degraded [53]. Hemopexin 
may also be responsible for the systemic delivery of intravenously administered heme 
to human patients suffering from blood disorders [70,71]. Another intercellular 




circulating hemoglobin to monocytes and macrophages, leading to heme degradation 
and the recycling of iron [53]. Knockout studies in mice have revealed that whereas 
hemopexin and haptoglobin are proteins needed to buffer hemolytic stresses, they are 
not required for successful erythropoiesis [72]. 
Recently, HRG-3, a secreted protein in C. elegans was identified that is 
required for delivering heme from maternal intestine to developing embryo. Whereas 
deletion of HRG-3 had no obvious effect on adult worms, more than 30% of embryos 
from HRG-3 mutant mothers failed to hatch and all the hatched progeny were growth 
arrested at the first larval stage. These growth phenotypes were only observed when 
the mutant worms were grown under low heme conditions. Ectopic expression of 
HRG-3 in maternal intestinal tissues rescued heme-limited growth arrest of HRG-3 
mutant worms, whereas expression in the embryos did not [73]. Collectively, this 
work demonstrates that HRG-3 binds to and delivers heme to the embryo from adult 
tissues.  It is reasonable to speculate that during development and erythropoiesis, a 
heme chaperone is required to facilitate the targeted delivery and redistribution of 
heme between certain tissues and cell types, which could not be achieved by the liver-
produced, high-affinity binding proteins, hemopexin or haptoglobin. Consequently, 
even though a HRG-3 mammalian homolog has not been discovered, a functional 
homolog of HRG-3 can be expected in mammals. 
 




Senescent red blood cells (RBCs) are constantly removed from the circulation 
by macrophages that also play a principal role in the breakdown of heme and the 
recycling of iron. Heme is released from lysed RBCs within phagolysosomes and is 
degraded by heme oxygenase-1 (HO-1) in the endoplasmic reticulum [33]. The first 
step is breakdown of heme by HO-1 into biliverdin, carbon monoxide and iron. The 
second step of the heme degradation pathway is the catalysis of biliverdin to bilirubin 
by biliverdin reductase. HO-1 also catalyzes the breakdown of free heme that is not 
bound to any protein, acting as a scavenger to prevent toxicity from free heme. 
Germline deletion of HO-1 leads to anemia in mice and published work suggests that 
HO-1 may play a cell-autonomous role in erythroblast differentiation [74]. Irradiated, 
wild-type recipient mice transplanted with HO-1+/- bone marrow cells have 
significantly fewer splenic erythroid precursors [75], indicating that HO-1 may be 
required for erythropoiesis both directly by promoting RBC maturation as well as 
indirectly by regulating systemic iron recycling. The degradation of heme in 
macrophages releases iron that is either stored as ferritin-bound iron or exported out 
of macrophages by the iron exporter, ferroportin-1 (FPN1, SLC40A1)[33].  
Circulating iron is bound by the sequestration protein transferrin and the 
transferrin–iron complex can be internalized by the ubiquitously expressed transferrin 
receptor which permits cells to acquire iron for various functions [16,33]. The 
importance of heme degradation and iron recycling in erythropoiesis is underscored 
by findings that inactivation of the heme degradation machinery in mice is associated 
with anemias [74,76,77]. In particular, specific ablation of FPN1 in macrophages is 




Figure 1.3. Proposed model of heme iron recycling following 
erythrophagocytosis. Senescent RBCs are specifically recognized and engulfed by 
BMDM inside an erythrophagosomal compartment. During this process, Nramp1 is 
recruited at the phagosomal membrane. After hemoglobin degradation, heme is 
transported through the phagosomal membrane via HRG-1. Once in the cytosol, heme 
can be transported outside the cell via FLVCR1. Additionally, cytosolic heme is 
degraded by HO-1. Freed heme iron is then recycled to the circulation via Fpn or is 





















defects are not intrinsic to erythroblasts but rather associated with iron recycling by 
the reticuloendothelial system [76]. Interestingly, we and others have recently found 
that, in addition to lysosomal localization in HEK293 cells [58], the heme transporter 
HRG-1 is also recruited and colocalizes with Nramp1 at the erythrophagosomal 
membrane, surrounding ingested RBCs in bone marrow derived macrophages 
(BMDMs) (Fig. 1.3) (C. White et al, unpublished obsevations and [78]). However, the 
absence of HO-1 at this location indicates that during erythrophagocytosis (EP), at 
least a portion of heme released from degraded hemoglobin is mobilized by HRG-1 to 
the cytoplasm [78]. The cytosolic heme can then undergo intracellular redistribution 
including degradation by HO-1 for iron recycling, or be exported by FLVCR1.  
 
Heme-regulated transcription and translation  
Heme is a key regulator of several processes at the transcriptional level. 
Rajagopal et al identified 288 genes in C. elegans that are transcriptionally regulated 
by heme [58]. Heme may also promote erythroid differentiation by enhancing the 
expression of p18 and p21 which are negative regulators of the cell cycle. Adult 
hemoglobin is produced in erythroid tissue and consists of a heme molecule bound to 
a tetramer of two α-globin chains and two β-globin chains. In low heme conditions, it 
is necessary to downregulate globin chain production because aggregation of globins 
is toxic to an erythroid cell [79]. The transcriptional regulation of globin production 
by heme is mediated through Bach1, the first mammalian transcription factor shown 




(MAREs) and repress transcription when Bach1 is not bound to heme. As heme is 
sufficient, heme binding to Bach1 will result in its dissociation from DNA and export 
from the nucleus [83]. Bach1 has four cysteine proline (CP) heme regulatory motifs, 
which are responsible for heme binding. Deletion of these motifs inhibited Bach1 
dissociation from MAREs upon the addition of excess heme. The heme degrading 
enzyme, HO-1, is similarly regulated by Bach1 [84]. In addition, hHRG-1 was also 
recently identified as a target of BACH1 in microarray expression analysis and ChIP-
Seq experiments, further suggesting that HRG-1 may be an important player in 
erythropoiesis [85].  
Heme is also involved in microRNA processing [12,86]. MicroRNAs are short 
RNAs that play a role in gene regulation at the transcriptional and post-transcriptional 
levels. This process is at least in part regulated by heme. A number of microRNAs are 
involved in different stages of erythropoiesis [87,88,89,90]. For example, an upstream 
regulatory element, which binds GATA-1 is required for the upregulation of a single 
pri-miRNA (precursor-RNA) that encodes both miR144 and miR451. Zebrafish 
depleted of miR451 showed impaired maturation of erythroid precursors, indicating 
that post-transcriptional regulation by microRNAs is essential for erythropoiesis [87]. 
In erythropoiesis, late-stage erythroblasts lose their nuclei to become 
reticulocytes. As they mature into erythrocytes over the next few days, they 
synthesize hemoglobin and other erythroid-specific proteins. Hemoglobin production 
must be coordinated with heme availability because aggregation of globin chains is 
toxic to the cell. As discussed above, globin chain production is regulated by heme at 




globin genes. However, mechanisms must exist to regulate globin production after the 
cell has lost its nucleus and transcriptional regulation is no longer possible. In 
reticulocytes, this regulation is achieved at the translational level by heme regulated 
eIF-2 (HRI) kinase [91,92]. In low heme conditions, when synthesis of globin chains 
needs to be downregulated, HRI is activated. Activated HRI phosphorylates serine 51 
of the α-subunit of the initiation factor (eIF-2). eIF-2 is normally responsible for 
recruiting the initiator tRNA to the pre-initiation complex, but phosphorylation 
prevents eIF-2 from being utilized for translation, resulting in global reduction in 
mRNA translation. Although the mechanism that HRI uses for heme sensing remains 
to be elucidated, it was recently demonstrated that His119, His120, and Cys409 are 
the ligands for heme binding. Also, the proline residue adjacent to the Cys409  is 
important for heme Fe
3+ 
complex binding [93]. 
 
Heme transport in pathogens 
Heme uptake in bacterial pathogens 
Compared to eukaryotes, heme uptake and transport have been well-
characterized in bacteria. In pathogenic bacteria, iron is crucial to infect the host.  As 
a defense mechanism against pathogens, the host must restrict access to iron and 
heme. This restriction of iron and heme to pathogens poses a serious problem that the 
bacteria must overcome for survival. While most bacteria secrete high-affinity, low-




requirements by utilizing host heme or heme-containing proteins, or by secreting 
hemophores (Fig. 1.4) [94].  
Heme uptake systems are classified into two groups: a) those that involve 
direct binding of heme or hemoproteins by outer membrane receptors, and b) those 
that involve secretion of hemophores that bind the heme source and deliver it to 
specific receptors [94]. There are 29 outer membrane heme receptors that have been 
identified from different species of gram-negative bacteria. Although these receptors 
share between 21 to 90% homology when compared to each other, they all share a 
highly conserved amino acid motif FRAP(10X)H(XX)NPL(2X)E [95].  
The outer membrane receptors can be divided into subgroups. A first 
subgroup of outer membrane receptors is not substrate-specific and binds either heme 
or heme-containing proteins. Such receptors are found in Yersinia enterocolitica, 
Escherichia coli and Shigella [94]. Outer membrane receptors, such as HemR in Y. 
enterocolitica, bind heme and actively transport it across the outer membrane into the 
bacterial periplasm. An intact Ton system, with the cytoplasmic membrane proteins 
ExbB and ExbD and membrane-anchored protein TonB, is required to provide energy 
for heme transport across the outer membrane. The TonB system uses a proton-
motive force for the passage of heme into the periplasm. Heme is bound by a 
periplasmic heme binding protein such as HemT and then delivered to permeases on 
the cytoplasmic membrane, such as HemU and HemV in Y. enterocolitica [96]. 
Transport of heme across the cytoplasmic membrane requires expenditure of ATP. In 




Figure 1.4. Heme acquisition by gram-negative bacteria. (A) Hemolysin secreted 
by bacterial cell degrades RBC, releasing Hb and heme. Once released, heme may be 
transported into the bacterial cell by different mechanisms i) direct binding of 
hemoglobin or heme to a specific TonB-dependent outer membrane receptor results 
in transport of heme into the periplasm. ii) Capture of hemoproteins such as 
hemoglobin or hemopexin by hemophores, which deliver these hemoproteins to a 
specific TonB-dependent outer membrane receptor. iii) Degradation of hemoproteins 
by either membrane bound or secreted bacterial proteases to release heme. (B) Heme 
bound by TonB-dependent outer membrane receptors is transported into the 
periplasm. TonB in association with the ExbB and ExbD proteins provides energy for 
this process. The transport of heme through the cytoplasmic membrane occurs via a 
system composed of a cytoplasmic membrane-associated permease and an ATPase. 
Heme oxygenase-like enzymes degrade heme in the cytoplasm.  (Adapted from 








The second subgroup of receptors is substrate-specific and binds only one or 
two sources of heme. These heme receptors are found in Vibrio, Neisseria and 
Haemophilus and these receptors have high affinity binding sites for one or two 
particular heme sources such as hemoglobin and or haptoglobin-hemoglobin (Hp-Hb) 
complexes [95]. The neisserial Hp-Hb and Hb receptor, HpuAB, is the only system 
with two outer membrane receptors, HpuA and HpuB. While HpuA is an outer 
membrane lipoprotein, HpuB is a TonB-dependent receptor that is similar to other 
TonB-dependent receptors. It has been shown that both proteins are required for Hb, 
Hpt-Hb and apo-haptoglobin binding. But it is not clear as to whether HpuA and 
HpuB have similar binding affinities for holo- versus apo-haptoglobin [95].  
Several gram-negative bacteria secrete small extracellular proteins called 
hemophores. Hemophores are secreted by ABC transporters in a manner dependent 
on their carboxy-terminal secretion signal [97]. Hemophores bind heme and deliver it 
to specific outer membrane receptors. One of the best-studied systems is the HasA-
HasR mediated heme uptake in Serratia marcescens. While usually the role of 
hemophores is to bind free heme or Hb-bound heme, the hemophore, HasA, secreted 
by HasDEF in S. marcescens extracts heme from hemoproteins. The free heme is then 
delivered to the outer membrane receptor HasR [98,99,100]. HasR can transport 
either free heme or heme from hemoglobin, but the presence of HasA promotes heme 
uptake to a greater extent. The mechanism of heme transfer to HasA from 
hemoglobin is not understood. It is thought that hemoglobin loses its heme moiety in 




acquisition systems have been identified in Porphyromonas gingivalis and the human 
pathogenic strain of Escherichia coli [102,103].  
The only known bacterial system that utilizes heme bound to hemopexin is the 
HuxA hemophore system found in Haemophilus influenzae [104]. H. influenzae does 
not make heme and the HuxABC gene cluster found in these bacteria allows it to 
utilize hemopexin, a heme-binding blood plasma protein very efficiently. HuxA is 
actively secreted by HuxB and is absolutely required for the utilization of heme-
hemopexin complexes [95].  
Some gram-negative bacteria secrete proteases that degrade host hemoproteins 
to release heme. A heme binding protein in E. coli EB1 strain possesses proteolytic 
activity, as it is able to degrade hemoglobin [104]. Porphyromonas gingivalis, a 
gram-negative anaerobic bacterial pathogen, secretes a class of protease called 
gingipains [105]. Of the several gingipains, the lysine-specific cysteine protease Kgp 
has been shown to both bind and degrade hemoglobin, hemopexin and haptoglobin 
[63]. As heme is an essential nutrient for most pathogenic bacteria, the virulence of 
pathogenic bacteria can be affected by targeting heme uptake pathways. Mutations in 
heme-iron uptake genes in Staphylococcus aureus reduce its pathogenicity in the 
invertebrate animal model, C. elegans [106]. In Bordatella pertussis, the bacterial 
agent responsible for whooping cough in humans, heme utilization by the bacteria 
contributes to bacterial pathogenesis in a mouse infection model [107].  
 




While several bacterial heme uptake and transport systems have been well 
characterized, only recently have proteins involved in heme uptake been identified in 
primitive eukaryotes. In pathogenic yeast, Candida albicans, RBT5 and RBT51 have 
been identified as heme uptake genes. Rbt5 and Rbt51 are mannosylated GPI- 
anchored proteins, and Rbt5 is highly induced upon iron starvation [108]. Despite 
70% homology between the two genes in C. albicans, RBT5 played a more important 
role than RBT51 in utilization of heme as an iron source. Disruptions in these genes 
did not reduce the virulence of C. albicans in murine models [109]. C. albicans 
possesses a heme-oxygenase enzyme (CaHMX1) that shares 25% identity with the 
human HO, and CaHMX1 is positively regulated by both heme and hemoglobin 
[110]. Whether heme iron utilization is essential for pathogenicity would be best 
addressed by using mutants such as Cahmx1Δ or Cahmx1Δ and CaRbt5Δ double 
mutants that are devoid of the ability to use the heme as an iron source [111]. Recent 
studies indicate that CaHMX1 plays a role in the pathogenesis of disseminated 
bloodstream infections by limiting the host immune response [112]. 
 
Heme transport in Trypanosomatids 
Trypanosomes are parasitic protists that cause significant human and animal 
diseases worldwide, such as Trypanosoma brucei (sleeping sickness or African 
trypanosomiasis), Trypanosoma cruzi (Chagas’ disease or American 
trypanosomiasis), and Leishmania spp.(leishmaniasis) [113]. The life cycle of these 




hosts. They lack some or all components of the heme biosynthetic pathway and are 
dependent on the uptake of heme from their hosts [13,14].  
Koreny et al proposed that the ancestor of all trypanosomatids is completely 
deficient in the ability to synthesize heme [114]. In some trypanosomatids like 
Leishmania spp., the pathway is partially rescued by genes encoding enzymes for the 
last three steps, possibly obtained by horizontal gene transfer from their host. 
Leishmania spp. can grow in media in which hemin is replaced by protoporphyrin IX, 
indicating that at least the last enzyme of the pathway, FECH, remains functional 
[13,115,116].  By contrast, trypanosomes lack all the enzymes for heme synthesis and 
in vitro cultivation of Trypanosoma requires the addition of heme compounds in the 
form of hemoglobin, hematin, or hemin to the medium [13,117]. T. cruzi proliferation 
is mediated almost exclusively by heme through unknown mechanisms. Treatment 
with SnPPIX, ZnMPIX and PdMPIX inhibit parasite proliferation, which is reverted 
by adding excess of heme [118]. A recent study reported TbHpHbR as a bloodstream 
stage-specific protein. TbHpHbR directs the internalization of heme carried by the 
haptoglobin-hemoglobin (Hp-Hb) complex into hemoproteins in order to optimize 
growth of bloodstream forms. However, TbHpHbR is only present in T. brucei; it is 
not found in the related kinetoplastids, T. cruzi or Leishmania [119].  
Huynh et al recently identified Leishmania Heme Response-1 (LHR-1) as the 
first Trypanosomal heme transporter [120]. LHR-1 is a homolog of CeHRG-4 and is 
localized to the plasma membrane and endocytic compartments in the parasites. 
Episomal expression of LHR-1 increased the intracellular heme concentration of 




to allow recovery of viable parasites lacking both copies of the gene, suggesting it is 
an essential component for heme uptake and survival. Functional assays in yeast 
demonstrated that LHR-1 can transport heme directly [120]. The ATP-binding 
cassette protein LABCG5 was also recently proposed to mediate the salvage of heme 
released after lysosomal degradation of internalized hemoglobin in L. donovani. This 
intracellular process for heme salvage from degraded hemoglobin was proposed to be 
distinct from the pathway directly promoting porphyrin transport into the parasites 
[121]. 
 
Heme transport in parasitic worms 
Helminthic infections are a huge burden to both public health and agriculture. 
More than two billion people are afflicted by helminthiasis, and agricultural losses 
due to plant-parasitic nematodes are estimated to be approximately eighty billion 
dollars annually [122,123]. Drug resistance is widespread, and there is a need to find 
new drug targets to eliminate these infectious agents [124]. Genomic analysis of 
heme biosynthetic enzymes has revealed that C. elegans lacks orthologs for these 
enzymes [15]. Heme biosynthetic enzyme activity measurements confirmed that C. 
elegans lack the ability to make heme [15]. We have additionally shown that other 
free-living nematodes such as Panagrellus redivivus, Oscheius myriophila and 
Paragordius varius and parasitic nematodes such as Strongyloides stercoralis, 
Ancylostoma caninum, Haemonchus contortus, Trichuris suis and Ascaris suum lack 




of these nematodes indicates that they encode abundant hemoproteins, suggesting the 
possibility that they must acquire heme from their environment. Like heme uptake in 
C. elegans, this process may involve homologs of HRG-1 [58].  
Published reports have suggested a role for heme in the pathogenicity of 
different parasitic worms. Hookworm infections due to Ancylostoma ceylanicum are 
prevalent in developing countries and are associated with iron deficiency anemia. A 
recent study demonstrated the importance of host iron status as a key mediator of 
hookworm pathogenicity [125]. Animals fed a reduced iron diet leading to anemia 
had a significant reduction in the intestinal load of worms. This observation suggested 
that hookworms rely on host heme-iron for their growth and development and that 
treatment of hookworm infection with anthelminthic drugs in combination with iron 
supplements to prevent anemia might exacerbate the severity of infection. Since 
hookworms, like C. elegans, also lack the ability to make heme, another plausible 
explanation given by the authors was that animals fed a low-iron diet have reduced 
worm burden due to inadequate amounts of heme for hookworm metabolism 
[15,125].   
Brugia malayi, a filarial nematode, is the causative agent of lymphatic 
filariasis that is endemic in Asia. Analysis of the of the B. malayi genome revealed 
the absence of the heme biosynthesis enzymes in these parasites [126]. Therefore, it is 
highly likely that these parasites obtain heme from their host or from Wolbachia 
(wBm), an intracellular endosymbiotic bacterium. Wolbachia has an intact heme 
pathway (except HemG, which may be substituted by a functional HemY) and a 




heme for the nematode. Antibiotics that eliminate the endosymbiont have inhibitory 
effects on the development and fertility of the parasitic nematode and have been used 
to treat patients with filariasis. Since heme is important for the growth and 
development of the nematode, another potential drug target is the heme uptake 
pathway in B. malayi or the heme biosynthesis pathway of Wolbachia [127,128].  
 
In summary, heme is essential for nearly all living organisms. Heme 
homoestasis is maintained through tight regulation of heme biosynthesis and 
degradation, as well as heme transport and trafficking. Understanding the mechanism 
of heme transport will significantly facilitate exploration of human genetic disorders 





Chapter 2: Materials and Methods 
 
Plasmid Construction  
To make yeast expression plasmids, the open reading frame (ORF) of 
CeHRG-1, CeHRG-4 and their hemagglutinin (HA) epitope-tagged versions were 
amplified by PCR from pcDNA3.1(+)zeo-CeHRG-1-HA and pcDNA3.1(+)zeo-
CeHRG-4-HA[58], respectively, using gene specific primers containing BamHI and 
XbaI sites, digested, and ligated to pYES-DEST52 vector (Invitrogen) digested with 
the same enzymes. Codon optimized hHRG-1 ORF for yeast expression (yhHRG-1) 
was synthesized by Genscript (OptimumGene) and subcloned into pYES-DEST52 
vector as described above. The ORF of hFLVCR2 (GenBank accession number 
BC019087) was PCR amplified from human FLVCR2 cDNA in pOTB7 (Clone ID 
4866427, Open Biosystems) using gene specific primers and cloned into pYES-
DEST52 vector as described above. Site-directed mutagenesis was performed on 
pcDNA3.1(+)zeo-CeHRG-1-HA and pcDNA3.1(+)Zeo-CeHRG-4-HA using the 
QuikChange XL Site-Directed Mutagenesis Kit following to the manufacturer’s 
instructions (Stratagene). The sequences of primers used for generating mutations are 
listed in Appendix I. The sequences coding mutant proteins were sequenced and 
subcloned into pYES-DEST as described above. 
Chimeras were generated from pcDNA3.1(+)zeo-CeHRG-1-HA, 




The sequences of primers used for generating chimeras are listed in Appendix I. The 
chimeras were cloned into pcDNA3.1(+)zeo using 5’ BamHI and 3’ XhoI sites. The 
constructs were subsequently cloned into the pECFP-N1 vector using 5’XhoI and 3’ 
BamHI sites, and subcloned into pYES-DEST vector using 5’BamHI and 3’ XbaI 
sites. 
For the HRG-1 small molecule antagonist screen, codon optimized ORFs of 
HRG-1 homologs from Leishmania amazonesis (yLHR-1), Brugia malayi 
(yBmHRG-1), Ancylostoma ceylanicum (yAceHRG-1), Dirofilaria immitis 
(yDiHRG-1), Meloidogyne incognita (yMiHRG-1), Trypanosoma brucei (yTbHR-1) 
and Trypanosoma cruzi (yTcHR-1) were synthesized by Genscript (OptimumGene) 
and subcloned into pYES-DEST52 vector using 5’BamHI and 3’XbaI sites. The yeast 
integrating plasmid pRS403 was used to generate integrated yeast cell lines. The 
GAL1 promoter/HRG-1 ORFs/CYC1 terminator expression cassette were amplified 
by PCR using 5’-NotI-GAL1/3’-SalI-CYC1tt primers from corresponding pYES-
DEST52 constructs, and subcloned into the NotI/SalI sites of pRS403 vector. 
 
Yeast Assays 
Yeast Strains and Growth Media 
The S. cerevisiae strains used in this study were derived from the W303 and 
YPH499 backgrounds (Appendix II). The hem1(6D) and OPY102 strains were 




fre2MET3-FRE1, plasmid pRS404-MET3-FRE1 was linearized with NdeI and 
integrated into the TRP1 locus of OPY102. Cells were maintained in YPD or 
appropriate synthetic complete (SC) media supplemented with 250 M -
aminolevulinic acid (ALA) (Frontier Scientific)[131]. 
To generated integrated yeast cells, pRS403 and the expression construct, 
pRS403-pGAL1-HRG-1 ORFs, were linearized at the unique NheI site in the HIS3 
gene and transformed into the W303 strain using the lithium acetate method [132]. 
Integrated clones were screened on 2% w/v glucose SC -His plates, using yeast 
colony PCR for both sides of the integration site as described below. The primers 
used for PCR are listed in Appendix A; the expected product sizes were 1461 bp for 
5’-B1-pRS403/3’-His3 primers and 1416 bp for 5’-His3/3’-A2-pRS403 primers.  
Integrated yeast lines were then tested by growing in 2% w/v raffinose SC (-His, 
+0.4% galactose) medium supplemented with different concentrations of GaPPIX. 
Isolated yeast stable lines were stored as frozen stocks containing 25% glycerol at -
80ºC. 
 
Yeast Colony PCR 
To examine yeast integration, a colony was resuspended using a disposable 
plastic loop with 1 µl volume in 100 µl of 40 µM Tris base (no pH adjustment), 0.5 
µM EDTA, 14 µM β-2-mercaptoethanol and 0.05% SDS. The cells were incubated at 
room temperature for 10 min followed by heating to 85–90°C for 10 min. After 




Lysate (1µl) was used per 25 µl PCR reaction (94°C, 1 min preheat; 94°C, 3 min to 
denature the genomic DNA; and 30 cycles of 94°C for 30 s, 50°C for 30 s, 68°C for 3 
min). 5 µl of the reaction product was then resolved on a 1% agarose gel. 
 
Spot Growth Assay 
The plasmids for HRG-1 wild-type and mutant expression were transformed 
into strain hem1(6D) using lithium acetate method [132]. Transformants were 
selected on 2% w/v glucose SC (-Ura) plates supplemented with 250 M ALA. Five 
or six transformed colonies were picked and streaked on 2% w/v raffinose SC (-Ura) 
plates supplemented with 250 M ALA to deplete glucose for 48 hours. Prior to 
spotting, cells were cultivated in 2% w/v raffinose SC (-Ura) medium for 18 hours to 
deplete hemin. Cells were then suspended in water to an OD600 of 0.2. Ten-fold serial 
dilutions of each tranformant were spotted (10 L /spot) onto 2% w/v raffinose SC (-
Ura) plates supplemented with either 0.4% w/v glucose and 250 M ALA (positive 
control), or 0.4% w/v galactose and different concentrations of hemin, incubated at 
30°C for 3 days before imaging. 
 
Ferrireductase Assay 
The strain hem1 fre1 fre2MET3-FRE1 was used for the ferrireductase 




respective SC auxotrophic medium supplemented with 250 M ALA. After being 
depleted of hemin in 2% w/v raffinose SC (-Ura, -Trp, -Met) medium for 12 hours, 
cells were suspended in 2% w/v raffinose SC (-Ura, -Trp) medium supplemented with 
0.4% w/v galactose, 0.1 mM Na2S and different concentrations of hemin to an OD600 
of 0.3, cultivated in 96-well plates at 30°C, with shaking at 225 rpm for 16 hours and 
assayed for ferrireductase activity [133]. Cells were washed with washing buffer (2% 
BSA, 0.1% tween-20 in 2× PBS) three to four times to remove residual hemin in the 
medium, washed twice with reaction buffer (5% glucose, 0.05 M sodium citrate 
buffer, pH 6.5),  suspended in reaction buffer and the OD600 determined using a plate 
reader (BioTek). Equal volume of assay buffer (2mM bathophenanthroline 
disulfonate (BPS), 2mM FeCl3 in reaction buffer) was added to the cells (T = 0 min) 
and incubated at 30°C in the dark until red color developed. OD535 and OD610 were 
determined and ferrireductase activity (nmol / 106cells / min) was calculated as: 
OD 	–	OD 	 	–	 OD 	–	OD 	 	 	45	
V 	 	 OD 	–	OD 	 	 	T
 
 
-Galactosidase Reporter Assay 
The plasmids for HRG-1 wild-type and mutant expression were co-
transformed into strain hem1(6D) with pCYC1-LacZ. Selection of transformants 
was performed as described above using appropriate SC auxotrophic medium 
supplemented with 250 M ALA. Cells were depleted for hemin in 2% w/v raffinose 




raffinose SC (-Ura, -Trp) medium supplemented with 0.4% w/v galactose, and 
different concentrations of hemin to an OD600 of 0.1. Cells culture were cultivated at 
30°C, with shaking at 225 rpm for 12 hours and assayed for -galactosidase activity, 




For western blotting experiments, yeast transformants were resuspended in 
lysis buffer (1% SDS, 8 M urea, 10 mM Tris-HCl pH 8.0, 10 mM EDTA) with 
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 4 mM benzamidine, 2 
g/mL leupeptin, and 1 g/mL  pepstatin) and 0.5 mm acid-washed glass beads. Cells 
were heated at 65°C for 10 min and disrupted using FastPrep-24 (MP Bio) for 3×30s 
at the 6.5m/s setting. Cell lysates were collected and the total protein concentration 
was quantified with the Bradford reagent (Bio-Rad). Protein samples were separated 
on 12% SDS-polyacrylamide gel and transferred to nitrocellulose membrane (Bio-
Rad). For immunoblotting, the membranes were incubated with rabbit anti-HA 
(Sigma) as primary antibody at a 1:5,000 dilution for 16 hours at 4°C, followed by 
HRP-conjugated goat anti-rabbit antibody at a 1:10,000 dilution for 1 hour at room 
temperature. Signal was detected using SuperSignal chemiluminescence reagents 






Yeast transformants were cultivated in 2% w/v raffinose SC (-Ura) medium 
supplemented with 0.4% w/v galactose and 250 M ALA to mid-log phase, and then 
fixed with 4% formaldehyde for 1 hour at room temperature. Immunofluorescence 
microscopy was performed as described elsewhere [134]. Images were taken using a 
DM IRE2 epifluorescence microscope (Leica) connected to a Retiga 1300 cooled 
Mono 12-bit camera. 
 
High-Throughput Screen 
Yeast integration lines were streaked on 2% w/v raffinose SC –His plates 
from -80°C glycerol stocks, and incubated at 30°C for 3 days until colonies with pink 
color formed. The day before adding the compounds, a 10 to 20μL aliquot of yeast 
cells were collected from the plate and inoculated in 50mL 2% w/v raffinose SC –His 
liquid medium at 30°C, with shaking at 250 rpm for 24 to 30 hours. To prepare the 
assay culture, 2% w/v raffinose SC (–His, +0.4% galactose) medium supplemented 
with 2 to 20μM GaPPIX was loaded (35μL/well) into 384-well plates (Nunc) using a 
Multidrop reagent dispenser (TiterTek). The plates were then loaded with 0.7μL 
compound/well (5µM) using robotic liquid handlers (Beckman). Yeast cells were 
prepared by centrifuging the overnight liquid culture at 3,000g for 5 min and 
resuspending in 2% w/v raffinose SC (–His, +0.4% galactose) to an OD600 = 0.1. 




a humidity container at 30°C without shaking. After 33-42 hours incubation, the 
OD600 was measured using a Synergy 2 plate reader (BioTek). 
DRC assays were performed as described above with the following 
modifications. All the compounds were validated by LC/MS and prepared as fresh 
10mM stocks in DMSO just before dispensation. Twelve different concentrations (0.1 
nM to 30 µM) of the compounds were then prepared from the stocks in a master 
plate. Compounds (0.7μL/well) were loaded into 384-well plates using an Echo 555 




Worm Culture and Strains 
C. elegans strains were maintained on nematode growth medium (NGM) agar 
plates seeded with OP50 bacteria at 20°C. Worm synchronization and cross were 
performed as described elsewhere [135]. The deletion strains hrg-1 (tm3199) 
andhrg-4 (tm2994) were obtained from the National Bioresource Project (Japan). 
The deletion strains were outcrossed eight times with the N2 Bristol strain before 
further study. A hrg-1hrg-4 double deletion strain was generated by crossing 
hrg-1 with hrg-4; homozygous mutant progeny and their wild-type brood mates 
were picked by single-worm PCR genotyping. A hrg-1hrg-4unc-119 strain was 




in liquid mCeHR-2 medium supplemented with 20 M hemin chloride [136]. For 
single-worm PCR, individual worms were lysed in 5 μL lysis buffer (50 mM KCl, 10 
mM Tris-HCl, 2.5 mM MgCl2, 0.45% NP-40, 0.45% Tween-20, 0.01% gelatin, and 
1mg/mL freshly prepared proteinase K) by freezing and heating (2 hours at -80°C, 1 
hour at 65°C, and 30 min at 95°C). Worm lysates were subjected to PCR reactions 
with primers CeHRG-1_del_f and CeHRG-1_del_b to detect a 650 bp fragment of 
hrg-1 in the hrg-1 strain, and with primers CeHRG-4_del_f and CeHRG-4_del_b to 
detect a 450 bp fragment of hrg-4 in the hrg-4 strain (Appendix A). 
 
Generation of Transgenic Worms 
The rescue plasmid Phrg-1::HRG-1-HA::ICS::GFP was constructed by 
recombining the putative hrg-1 promoter (~3 kb upstream of hrg-1 gene, Phrg-1), the 
fused hrg-1 gene (HRG-1-HA::ICS::GFP) and the 3’-UTR of hrg-1 gene into a single 
destination vector, pDEST-R4-R3, using the Multisite Gateway system (Invitrogen). 
The entry clones of hrg-1 promoter and 3’-UTR were constructed previously [58]. To 
make the fused hrg-1 entry clone, hrg-1 gene was amplified by PCR from N2 
genomic DNA, tagged with the HA epitope, fused with the SL2 intercistronic 
sequence (ICS) and gfp gene, and cloned into the entry vector pDONR-221 by 
recombination using the Gateway BP Clonase kit (Invitrogen). Site-directed 
mutagenesis was performed on the rescue plasmid as described above. The promoter, 
coding region and 3’-UTR of all the rescue plasmids were sequenced before further 




Rescue plasmids  (10µg) were mixed with 5g of the unc-119 rescue plasmid 
pDP#MM016B and co-bombarded into hrg-1hrg-4unc-119 worms using the PDS-
1000 particle delivery system (Bio-Rad). At least two transgenic lines of each 
construct were analyzed for each experiment. 
 
Worm Growth Assay on ΔhemB E. coli  
The heme-deficient E. coli strain RP523 (ΔhemB) was a gift from Dr. Mark 
O’Brian at State University of New York at Buffalo [138]. Actively growing ΔhemB 
cells (grown overnight in Luria-Bertani (LB) medium supplemented with 1 µM 
hemin) were diluted at a ratio of 1:6 into fresh LB medium supplemented with 
different concentrations of hemin, cultivated for 5.5 hours, heat-inactivated at 65°C 
for 5 min, and diluted to a OD600 = 0.5 with corresponding LB medium. Each 35 mm 
NGM plate was seeded with 200L cell culture.  
Synchronized L1 larvae of worms grown on OP50 seeded NGM plates were 
transferred onto NGM plates seeded with ΔhemB grown with 50 µM hemin, and 
incubated at 20°C for 4 days (P0). The P0 worms were bleached when they reached 
gravid stage. Forty synchronized F1 L1 larvae were transferred onto each ΔhemB plate 
and inoculated at 20°C for 3-5 days. Five F1 gravid worms were placed onto each 
new appropriate ΔhemB plate and allow to lay eggs (F2) for 12 hours. The growth of 
F1 and F2 worms was recorded by DIC imaging and COPAS BioSort (Union 
Biometrica, Holliston, MA) when the wild-type worms reached young adult stage. 




(time of flight) and optical density (extinction). The settings for GFP measurement 
were gain=3.0, PMT voltage=600. 
 
Worm ZnMP Uptake Assay 
Worms were grown as described for the ΔhemB growth assay. F1 worms were 
harvest at L4 stage from ΔhemB plates, washed twice with M9 buffer. Approximately 
100 worms/well of F1 worms were transferred to 12-well plates, inoculated in 
mCeHR-2 medium supplemented with 1.5 M hemin chloride and different 
concentrations of ZnMP for 16 hours. ZnMP fluorescence intensity was scored using 
a DM IRE2 epifluorescence microscope (Leica) with a rhodamine filter and 
quantified by SimplePCI software [65,139]. 
 
Worm Immunoblotting 
Worms were grown as described for the ΔhemB growth assay. F1 worms were 
harvested at early gravid stage from ΔhemB plates, washed twice with M9 buffer, 
resuspended in lysis buffer (20 mM HEPES, pH 7.4, 0.5 % Triton X-100 and 150 
mM NaCl) with Protease Inhibitor Cocktail Set III (Calbiochem) and Lysing Matrix 
D beads (MP Biomedicals), and disrupted using FastPrep-24 (MP Biomedicals) for 
60s at the 6.5 m/s setting. The total protein concentration of worm lysates was 
quantified with the Bradford reagent (Bio-Rad) and subjected to immunoblotting 





Cell Lines and Transfection 
HEK293 and MDCK II cells were maintained in Dulbecco’s modified 
medium with 10% fetal bovine serum, 1% penicillin-streptomycin, and glutamine. 
MDCK II cells were kindly provided by the Lippincott-Schwartz laboratory (NIH, 
Bethesda, Maryland). Transfections for immunoblotting were performed with 
Lipofectamine 2000 (Invitrogen), and those for immunofluorescence were performed 
with FuGENE 6 (Roche). For immunoblotting, HEK293 cells were seeded on tissue 
culture plates and transfected with Lipofectamine 2000 the next day at a confluence 
of 90%. Lipofectamine transfection was performed according to the manufacturer’s 
protocol. Cells were harvested for immunoblotting two days after transfection. 
HEK293 cells for fluorescence microscopy were seeded on glass coverslips and 
transfected with FuGENE 6 the following day at a confluence of 50%. FuGENE 6 
transfection was performed according to the manufacturer’s protocol, and cells were 
fixed for microscopy two days after transfection. MDCK II cells were seeded on 
Corning transwell filters and allowed to form a monolayer. Before the cells had 
formed tight junctions they were transiently transfected using Lipofectamine 2000 
according to the manufacturer’s protocol. The formation of a monolayer was 
confirmed by trans-epithelial resistance readings in the range of 400-500 ohms. 
Rabbit anti-HA antibody (Sigma) was used for immunoblotting at a concentration of 





Immunoblotting of Mammalian Cell Lysate 
Transiently transfected cells were lysed in buffer containing 1% Triton X-100, 
20 mM Hepes pH 7.4 and 150 mM NaCl. Protein (35µg) was seperated on a 4-20% 
gradient SDS-PAGE gel and then transferred to nitrocellulose membrane (BioRad). 
Membranes were blocked with 5% nonfat milk for one hour, and then incubated for 
one hour in primary antibody in 5% milk. After six washes in phosphate-buffered 
saline with 0.05% Tween-20, blots were incubated with anti-rabbit horseradish 
peroxidase linked secondary antibody in 5% milk for 1 hour. Blots were washed 
again six times in phosphate buffered saline with 0.05% Tween-20, and then 
developed using Pico ECL reagents (Pierce). 
 
Immunofluorescence in Mammalian Cells 
Transiently transfected HEK293 or polarized MDCK II cells were fixed in 4% 
paraformaldehyde (PFA), quenched with 0.1M ethanolamine, and mounted on 
coverslips with Prolong Antifade (Invitrogen). HEK293 cells were stained before 
fixation with a plasma membrane marker (AlexaFluor633-conjugated wheat germ 
agglutinin) at 4 μg/ml for 5 minutes at 37ºC. HEK293 cells were co-transfected with 
Lamp-1 YFP and CFP tagged constructs. Lamp-1 YFP was a kind gift from Jennifer 
Lippincott-Schwartz. MDCK II cells were co-transfected with either the apical 
membrane marker, syntaxin-3 GFP, or the basolateral marker, NTCP GFP, and the 
HA tagged constructs. The MDCK II cells were then stained with anti-HA and 




with a Leica 510 confocal microscope using argon and neon lasers and a 63x oil 
immersion lens. 
 
Fluorescence Protease Protection Assay 
The FPP Assay was carried out as previously described [73]. HEK293 cells 
were grown in LabTeK cover glass culture chambers (Nunc) and transfected with 
pECFP-N1 HRG-1 chimera constructs. Cultures were incubated for 24 hours and then 
the cells were washed three times with KHM buffer (20 mM HEPES, PH 6.5, 110 
mM potassium acetate, and 2mM MgCl2). Images of selected cells were recorded 
using a DMIRE2 epifluorescence microscope (Leica) connected to a Retiga 
1300cooled Mono 12-bit camera. Time-lapse images were acquired before and after 
proteinase K (50mg/ml/3 minutes) digestion. Following this, the cells were treated 
with both 30 mM digitonin and proteinase K and images were recorded 1, 2 and 3 
minutes after treatment. 
 
Statistical Analysis 
Statistical significance was calculated by using one-way ANOVA with the 
Student–Newman–Keuls multiple comparison test in GraphPad INSTAT version 3.01 
(GraphPad, San Diego). Data values were presented as mean ± SEM. A p value < 




Chapter 3: Topologically conserved residues direct heme 
transport in HRG-1-related proteins 
Summary 
Heme (iron  protoporphyrin  IX)  is  a macrocycle that not only plays an 
essential role as a prosthetic group in proteins but is an essential nutrient for parasites 
and is the major dietary iron source for humans [53,140].  Because hemes are 
essential but cytotoxic when present in excess, organisms must maintain appropriate 
levels of cellular heme.  One means to accomplish this task is to regulate the synthesis 
and degradation of heme [16,141,142].  Another would be to regulate the trafficking 
and compartmentalization of heme [53]. While significant strides have been made in 
understanding the mechanisms and regulation of heme synthesis  and  degradation  in  
eukaryotes, how heme is transported, trafficked, and compartmentalized within the 
cell remains poorly understood [53].  Studies of heme transporters in bacteria have 
provided the molecular underpinnings into protein function [143,144], but these 
transporters do not have identifiable homologs in animals. 
By utilizing the free-living roundworm Caenorhabditis elegans, we 
previously identified HRG-1-related proteins, membrane-bound transporters which 
import heme [58].   HRG-1- related proteins have four paralogs in C. elegans - 
CeHRG-1, CeHRG-4, CeHRG-5, and CeHRG-6 which may function redundantly to 
ensure that the worm, a heme auxotroph, acquires an adequate supply of heme to 




homolog which is only ≈20% identical to CeHRG-1.   Previous studies have 
demonstrated that both worm and human HRG-1 bind and transport heme, and that 
knockdown of hrg-1 in zebrafish embryos results in severe anemia with concomitant 
defects in yolk tube extension and brain formation; phenotypes that are fully rescued 
by CeHRG-1 [58].  These studies predict that HRG-1-related proteins are essential for 
vertebrate development and have conserved functions across metazoa.  To gain 
mechanistic insights into the heme transport function of HRG-1-related proteins, we 
conducted a structure-function analysis of CeHRG-1 and CeHRG-4 by exploiting 
yeast mutants that are unable to synthesize heme. Our studies reveal that HRG-1-
related proteins transport heme across membranes through the coordinated actions of 
residues that are topologically conserved in the worm and human proteins. Our results 
imply that the mechanism for heme import employed by HRG-1-related proteins is 
ancient and predates vertebrate origins. 
 
Results 
CeHRG-1 and CeHRG-4 are both essential for heme homeostasis in C. elegans  
To determine the in vivo localization of HRG-1-related proteins, we generated 
transgenic worms that expressed CeHRG-1 and CeHRG-4 tagged at the C-terminus 
with GFP. Both genes were expressed in the worm intestine with CeHRG-4 localized 
to the apical plasma membrane and CeHRG-1 primarily localized within an 




Figure 3.1. Functional characterization of HRG-1-related proteins in C. elegans. 
(A) Transgenic worms stably expressing CeHRG-4::YFP or CeHRG-1::GFP 
translational fusions were cultivated in mCeHR-2 medium with 1.5 μM heme and 10 
μM ZnMP for 16 hours with constant shaking. The localization of GFP variants 
(green) and ZnMP (red) was examined using a Zeiss 710 confocal microscope. Boxed 
regions in the upper images have been enlarged for clarity and shown at the bottom. 
(B) Schematic representation of Δhrg-1 (tm3199) and Δhrg-4 (tm2994). Open boxes 
represent open reading frames and grey boxes indicate untranslated regions. “+1” 
indicates the transcription start site. The deleted regions are represented by underline 
with the start and end indicated above. (C) Wild-type, Δhrg-1, Δhrg-4 and Δhrg-
1Δhrg-4 worms were synchronized, placed on NGM plates seeded with RP523 
bacteria grown at 50 μM hemin (P0), synchronized again and transferred to RP523 
plates of low (1 μM) and high (50 μM) hemin (F1) and follow the growth for two 
subsequent generations. Representative images of F2 progeny are shown. Scale bar, 
50 μm. (D) Worms in (C) were measured by COPAS BioSort. Each dot represents an 
individual worm: wild-type (green), Δhrg-1 (orange), Δhrg-4 (blue) and Δhrg-1Δhrg-
4 (red). Time of flight and extinction indicate the length and the optical density of 









fluorescent heme analog zinc mesoporphyrin (ZnMP) revealed that CeHRG-1 
localized to vesicular membranes containing ZnMP fluorescence. These localization 
studies are consistent with our previous genetic knockdown experiments in worms 
which showed that ZnMP accumulated in vesicles when CeHRG-1 was depleted, 
while RNAi of CeHRG-4 reduced ZnMP entry into the intestine.  
To delineate the function of HRG-1-related proteins, we analyzed worms with 
a genetic deletion in hrg-1 and hrg-4. As shown in Fig. 3.1B, Δhrg-1 (tm3199) 
contains a 341 bp deletion which results in the loss of exon 1 (including 43 bp 
upstream of the ATG start codon), intron 1, and a portion of exon 2. By contrast, 
Δhrg-4 (tm2994) has a 202 bp deletion which eliminates part of intron 1, exon 2, and 
intron 2. PCR amplification of the genomic DNA from Δhrg-1 and Δhrg-4 confirmed 
the presence of these deletions (Appendix III). Analysis by RT-PCR from RNA 
extracted from Δhrg-1 strain revealed no discernible product, although a ≈450 bp 
fragment was amplified in RNA samples obtained from the Δhrg-4 deletion strain 
(Appendix III A). DNA sequencing of the 450 bp product revealed that a truncated 
CeHRG-4 protein containing the first two TMDs and six additional amino acids 
followed by several stop codons could be synthesized if the Δhrg-4 mRNA were to be 
translated (Appendix III B). Together, these results suggest that the Δhrg-1 strain is a 
null mutant whereas the Δhrg-4 strain could be a hypomorph.  
Since CeHRG-1 and CeHRG-4 are highly upregulated when worms are grown 
with low environmental heme, we analyzed the deletion mutants for heme-dependent 
phenotypes [145]. Neither Δhrg-1 nor Δhrg-4 showed any obvious phenotypes 




does not synthesize heme [73]. Feeding worms RP523 cultivated in different 
concentration of heme permits external control of heme levels within the worm via 
dietary manipulations. Because the C. elegans genome contains multiple paralogs of 
HRG-1-related proteins which may function redundantly, we generated a Δhrg-
1Δhrg-4 double mutant strain. Unlike the single mutants, the Δhrg-1Δhrg-4 mutant 
worms were significantly growth retarded in low heme corresponding to a delay of up 
to three larval stages during development (Fig. 3.1 C, D). Most importantly, this 
growth delay was fully suppressed when double mutant worms were fed a heme-
replete diet (Fig. 3.1 C, D). These genetic studies affirm that both hrg-1 and hrg-4 are 
essential for heme homeostasis in C. elegans when worms are maintained under 
minimal dietary heme conditions. Moreover, the additive phenotypes observed in the 
Δhrg-1Δhrg-4 double mutants indicate that the aberrant mRNA generated in Δhrg-4 
worms has little or no function.  
 
Expression of HRG-1-related Proteins in Saccharomyces cerevisiae hem1Δ Strain  
Our genetic investigations of C. elegans clearly indicate that CeHRG-1 and 
CeHRG-4 function in a concerted manner to maintain heme homeostasis in the worm. 
The presence of multiple paralogs of HRG-1-related proteins in C. elegans hinders a 
systematic investigation of the mechanisms employed by individual HRG-1-related 
proteins within the animal. To circumvent this complication, we sought to 
recapitulate the heme auxotrophy of C. elegans in a simpler, defined system. We 




related protein homologs and utilizes exogenous heme poorly even in the absence of 
endogenous heme synthesis [130,136]. A forward genetic screen in yeast had recently 
identified the porphyrin transporter Pug1p using sensitive, functional assays 
established to assess heme transport activity in hem1Δ strain, a yeast mutant that is 
deficient in HEM1 which encodes for 5-aminolevulinate synthase, the first enzyme of 
the heme synthesis pathway [130]. HRG-1-related proteins tagged at the C-terminus 
with a HA epitope was expressed in hem1Δ under the control of the inducible GAL1 
promoter, which was induced by adding galactose and repressed by adding glucose. 
When both CeHRG-1 and CeHRG-4 are expressed in yeast, their proteins migrated at 
the predicted molecular weights, similar to our earlier expression analysis in 
mammalian cell lines (Fig. 3.2A) [58]. Indirect immunofluorescence microscopy 
indicated that CeHRG-4-HA localized primarily on the plasma membrane, while 
CeHRG-1-HA was found on the yeast vacuolar membrane, a membrane compartment 
equivalent to the mammalian lysosome (Fig. 3.2B). These studies are consistent with 
expression studies of CeHRG-1 and CeHRG-4 proteins in worms (Fig. 3.1B) and 
mammalian cells [58].  
 
CeHRG-1 and CeHRG-4 Mediate Heme Transport in Yeast   
A hem1Δ yeast mutant is unable to grow unless it is supplemented with either 
ALA, the product of the 5-aminolevulinate synthase enzyme, or an excess of 




Figure 3.2. Improved hemin utilization in yeast strains overexpressing HRG-1-
related proteins. (A) Immunoblotting was performed on transformants 
overexpressing C-terminus HA-tagged CeHRG- 4 or CeHRG-1 in the hem1Δ(6D) 
strain. Predicted molecular mass of HRG-1-related proteins was detected as indicated 
by filled circles. Asterisks indicate putative dimers. (B) Same yeast transformants 
were subjected to indirect immunofluorescence microscopy. For clarity, the boxed 
regions in the left images have been enlarged to show the intracellular localization of 
HRG-1-related proteins. Scale bar, 5 μm. (C) The hem1Δ(6D) strain transformed with 
empty vector pYES-DEST52, CeHRG-4, CeHRG-1 and their HA-tagged versions 
were cultivated overnight in SC medium without ALA and spotted in serial dilutions 
on 2% raffinose SC (-Ura, +0.4% galactose) plates supplemented with indicated 
concentrations of hemin (positive control: +0.4% glucose, +250μM ALA, negative 
control: - ALA, -hemin). Plates were incubated at 30°C for 3 days prior to imaging. 
(D) The hem1Δfre1Δfre2ΔMET3-FRE1 strain was transformed with empty vector 
pYES-DEST52 and plasmids for HRG-1-related protein expression. Transformants 
were ALA-starved for 12 hours, grown in 2% raffinose SC (-Ura, -Trp, +0.4% 
galactose) medium supplemented with indicated concentration of hemin for 16 hours, 
and assayed for ferric reductase activity. (E) The hem1Δ(6D) strain co-transformed 
with pCYC1-LacZ and empty vector or plasmids expressing HRG-1- related proteins 
was ALA-starved for 12 hours, and grown in 2% raffinose SC (-Ura, -Trp, +0.4% 
galactose) medium supplemented with indicated concentration of hemin for 12 hours, 
lysed and β-galactosidase activity was measured. Error bars represent the standard 









three independent assays established in hem1Δ yeast mutants [130]. (a) First, we 
determined rescue of growth of hem1Δ strain transformed with a plasmid expressing 
HRG-1-related proteins and grown on agar plates containing varying concentrations 
of heme (Fig. 3.2C). The degree of growth rescue and the heme concentration 
indicates relative uptake of heme by HRG-1-related proteins. (b) Second, we 
measured the activity of a heme-dependent enzyme, ferric reductase [130,133], as an 
indicator of intracellular heme concentrations in a hem1Δfre1Δfre2ΔMET3-FRE1 
strain (Fig. 3.2D). This strain lacks both native genes for FRE1 and FRE2, the major 
surface reductases which are sensitive to regulation by iron and copper, but has one of 
these ferric reductases (Fre1p) present under the control of the inducible MET3 
promoter. Thus, any perturbations in cellular heme levels due to expression of the 
HRG-1-related proteins, are reflected in a concomitant change in the ferric reductase 
enzyme activity [130,133]. (c) Third, we measured changes in the regulatory pools of 
heme by determining β-galactosidase activity from a CYC1::lacZ promoter-reporter 
fusion (Fig. 3.2E). Here, lacZ expression is dependent on Hap1-5. Hap1 is a 
transcription factor that binds heme and activates CYC1 expression in response to 
cellular changes in heme [146,147]. Thus, the level of β-galactosidase activity in 
CYC1::lacZ expressing HRG-1-related proteins reflects the availability of regulatory 
pools of intracellular heme to activate the CYC1 promoter.  
The hem1Δ strain transformed with pYES-DEST52 vector alone did not grow 
unless supplemented with 2.5 to 10 μM heme. By contrast, cells overexpressing 
CeHRG-1 and CeHRG-4, either with or without a HA epitope tag, showed a 




imported heme was incorporated into cellular hemoproteins, because yeast expressing 
CeHRG-4 and CeHRG-1 showed >10-fold and 5-fold increase in ferrireductase 
activity, respectively (Fig. 3.2D). Furthermore, cells expressing HRG-1- related 
proteins had elevated cytoplasmic heme because CeHRG-4 and CeHRG-1 expression 
increased the activity of CYC1::LacZ reporter by 10 to 20-fold (Fig. 3.2E). In 
addition, CeHRG-5 and CeHRG-6 also significantly and consistently enhanced the 
heme-dependent growth of the hem1Δ strain confirming our in silico observations that 
these putative paralogs transport heme. (Fig. 3.3). Together, these studies 
unequivocally demonstrate that multiple HRG-1- related proteins transport heme in 
the worm and lend validity to the use of the yeast as a heterologous system to dissect 
the mechanism of HRG-1-related protein activity.  
 
Identification of conserved heme-binding ligands in HRG-1-related proteins  
Although multiple sequence alignments reveal only 27% identity and 41% similarity 
between CeHRG-1 and CeHRG-4, an examination of the two protein sequences using 
membrane topology modeling revealed highly conserved amino acids that are located 
within the protein’s predicted secondary structure that may function as axial ligands 
(H, Y or C) for heme (Fig. 3.4A). CeHRG-1 and CeHRG-4 are predicted to contain 
four transmembrane domains (TMDs) and both the amino and carboxyl terminus 
reside in the cytoplasm [58]. Conserved residues in CeHRG-1 include H88 and H90 
in TMD2, H135 in the second predicted exoplasmic (E2) loop, and in the carboxyl 




Figure 3.3. Worm HRG-1 homologs function as heme importers in yeast hem1Δ 
strain. The hem1(6D)  strain was transformed with empty vector pYES-DEST52, and 
c-terminus HA-tagged HRG-1 proteins. Spot growth assay were performed with 










Figure 3.4. Heme transport analysis of wild-type and mutant CeHRG-4. (A) 
Putative topology of CeHRG-4 and CeHRG-1 predicted by TMHMM 2.0 and 
SOSUI. The amino and carboxyl-termini are cytoplasmic, C1 is the cytoplasmic loop 
and E1 and E2 are the exoplasmic loops. Potential heme interacting residues are 
shaded in red. (B) The hem1Δ(6D) strain was transformed with empty vector pYES-
DEST52, CeHRG-4-HA and its mutants. Spot growth assay were performed with 
indicated conditions. Plates were incubated at 30°C for 3 days prior to imaging. (C) 
The hem1Δfre1Δfre2ΔMET3-FRE1 strain was transformed with empty vector pYES-
DEST52, CeHRG-4 and its mutants. Ferric reductase assays were performed with 
indicated concentrations of hemin. Ferric reductase activity (nmol / 106cells / min) 
was measured and normalized to the activity of vector. (D) The hem1Δ(6D) strain 
cotransformed with pCYC1-LacZ and empty vector pYES-DEST52, CeHRG-4 or its 
mutants. β-galactosidase activity was measured. Error bars represent the standard 
error of the mean (SEM) from three independent experiments. * p < 0.05, ** p < 0.01, 










Figure 3.5. Sequence alignment of CeHRG-1 and CeHRG-4. Pairwise sequence 
alignment was performed on CeHRG-1 and CeHRG-4 using EMBOSS Needle. 
Predicted transmembrane domains are shown as boxed region (TMD 1 - 4). 
Conserved amino acids shared by CeHRG-1 and CeHRG-4 are shaded in gray. 
Potential heme interacting motifs (red) and worm HRG-1 specific residues (green) are 








interact and orient heme side chains (Fig. 3.4A and Fig. 3.5). It is noteworthy that the 
potential His heme ligands in the TMD2 of CeHRG-1 are substituted with Tyr (Y61 
and Y63) in CeHRG-4 (Fig. 3.4A). Tyr, which preferentially binds ferric iron, forms 
heme ligands with a lower redox potential than His and the coordination stabilizes 
heme and prevents it from carrying out oxidative chemistry [148,149].  
 
CeHRG-4 Function Requires a Histidine in the E2 Loop and the FARKY Motif 
in the C-terminus   
To examine the role of specific residues for CeHRG-4 functions, we replaced 
Y61, Y63, H108 and FARKY with alanines (Fig. 3.4A and Fig. 3.5). Immunoblotting 
and fluorescence microscopy studies revealed comparable expression and localization 
of the mutant and wild-type proteins (Fig. 3.6). Heme-dependent growth of 
transformed hem1Δ strain showed reduced growth only for the H108A mutant (Fig. 
3.4B). By contrast, ferrireductase assays revealed a significant reduction in the 
activity for Y63, H108 and FARKY mutants, although only mutations in H108 and 
the FARKY motif resulted in severe attenuation (Fig. 3.4C). Although β-
galactosidase assays confirmed that substitutions of H108 and FARKY with Ala in 
CeHRG-4 significantly decreased cytoplasmic heme levels at low heme, the Y63A 
mutant had consistently reduced activity but was statistically not significant (Fig. 
3.4D). We found that the Y61A mutant did not alter the activity of heme-dependent 
reporters in any of the assays. The observation that only the H108A mutant showed 




Figure 3.6. Localization and expression of CeHRG-4-HA and mutants in yeast. 
(A) Indirect immunofluorescence microscopy was conducted on hem1(6D) strain 
transformed with empty vector pYES-DEST52, CeHRG-4-HA and mutants. Rabbit 
anti-HA was used as the primary antibody, and an AlexaFluo568-conjugated goat 
anti-rabbit antibody was used as the secondary antibody. Boxed regions were 
enlarged for clarity. Scale bar, 5 µm. (B) Immunoblotting was performed on 
transformants of CeHRG-4-HA and its mutants in the hem1(6D) strain. Predicted 
molecular mass of CeHRG-4 was detected as indicated by filled circles. Asterisks 
indicated putative dimers. The endogenous expression level of phosphoglycerate 










assay to residual heme transport activity in other mutants (Fig. 3.4B versus 3.4C, D). 
Collectively, these results strongly implicate H108 and the FARKY motif, and to a 
lesser extent Y63, in heme transport by CeHRG-4. 
 
CeHRG-1 Function Requires a Histidine in TMD2 and the C-terminus FARKY 
Motif  
Based on the primary amino acid sequence homology and secondary structure 
prediction of CeHRG-1 and CeHRG-4, we set out to establish whether select 
conserved amino acids were essential for heme transport by CeHRG-1 (Fig. 3.4A and 
Fig. 3.5). Mutations in H90 and the FARKY motif resulted in a dramatic reduction in 
growth compared to wild-type CeHRG-1 at low and high heme (Fig. 3.7A). By 
contrast, mutating H135 in the putative E2 loop resulted only in a slight growth delay 
even though each of the mutants were expressed and localized to the yeast vacuolar 
membrane (Fig. 3.8). Consistent with the growth assays, substitutions of H90 and 
FARKY with alanine resulted in significant reduction in ferrireductase and β-
galactosidase activities in low and high heme conditions (Fig. 3.7B and C). As 
observed in the growth assay, the H135A mutant showed reduction in ferrireductase 
and β-galactosidase activities at low heme which was alleviated by increasing the 
heme concentrations. As observed for the Y61A mutant of CeHRG-4, the equivalent 
H88A mutant showed no obvious defects indicating that this ligand does not 
compensate in the H90A mutant. Our results suggest that, under heme deplete 




terminus FARKY motif, and to a lesser extent H135 in the predicted E2 loop, for 
heme transport.  
To determine whether other potential heme-binding ligands (H, Y, or C) 
conserved in HRG-1-related proteins may compensate as secondary ligands in the 
site-directed mutants, we mutagenized H14 and H40 in the N-terminus, H41 and Y67 
in the E1 loop, and C97 and C127 in a highly conserved CLV motif within TMD3, of 
CeHRG-4 and CeHRG-1, respectively (Fig. 3.5 and Fig. 3.9). Mutating each of these 
residues to Ala did not significantly alter the function of either CeHRG-1 or CeHRG-
4 suggesting the predominant heme ligands in both proteins are the His in the E2 
loop, the His or Tyr in TMD2 and FARKY motif in the C-terminus.  
 
H90A has dominant-negative effects on CeHRG-1 function in C. elegans. 
Because C. elegans contains multiple paralogs of HRG-1-related proteins, and 
as neither Δhrg-1 nor Δhrg-4 single mutants have obvious phenotypes, we generated 
hrg-1 transgenic worms in the Δhrg-1Δhrg- 4 double mutant strain to verify our yeast 
results in vivo. The constructs were created by putting hrg-1 and gfp under the control 
of the hrg-1 promoter (~3 kb upstream of hrg-1 gene, Phrg-1) separated by the SL2 
intercistronic sequence (ICS) from rla-1 (Fig. 3.10A). In the transgenic worms, the 
HRG-1::ICS::GFP transgene is transcribed as a single polycistronic mRNA, but 
yields two separate proteins: HRG-1 and GFP. Thus, GFP fluorescence is indicative 
of transgene expression. The CeHRG-1 and H88A mutant transgenic worms did not 




Figure 3.7. Heme transport analysis of wild-type and mutant CeHRG-1. (A) The 
hem1Δ(6D) strain was transformed with empty vector pYES-DEST52, CeHRG-1-HA 
and its mutants. Spot growth assay were performed with indicated conditions. Plates 
were incubated at 30°C for 3 days prior to imaging. (B) The 
hem1Δfre1Δfre2ΔMET3-FRE1 strain was transformed with empty vector pYES-
DEST52, CeHRG-1 and its mutants. Ferric reductase assay were performed with 
indicated concentrations of hemin. Ferric reductase activity (nmol / 106cells / min) 
was measured and normalized to the activity of vector. (C) The hem1Δ(6D) strain co-
transformed with pCYC1-LacZ and empty vector pYES-DEST52, CeHRG-1 or its 
mutants. β-galactosidase activity was measured. Error bars represent the standard 
error of the mean (SEM) from three independent experiments. * p < 0.05, ** p < 0.01, 










Figure 3.8. Localization and expression of CeHRG-1-HA and mutants in yeast. 
(A) Indirect immunofluorescence microscopy was conducted on hem1(6D) strain 
transformed with empty vector pYES-DEST52, CeHRG-1-HA and mutants. Rabbit 
anti-HA was used as the primary antibody, and an AlexaFluo568-conjugated goat 
anti-rabbit antibody was used as the secondary antibody. Boxed regions were 
enlarged for clarity. Scale bar, 5 µm. (B) Immunoblotting was performed on 
transformants of CeHRG-1-HA and its mutants in the hem1(6D) strain. Predicted 
molecular mass of CeHRG-1 was detected as indicated by filled circles. Asterisks 
indicated putative dimers. The endogenous expression level of phosphoglycerate 










Figure 3.9. Mutagenesis of worm specific potential heme ligand did not affect 
HRG-1 function. The hem1Δ(6D)  strain transformed with empty vector pYES-
DEST52, CeHRG-4-HA, CeHRG-1-HA and alanine substitutions of 
histidines/tyrosines at the amino-terminus, E1 loop, and a CLV motif in TMD3. Spot 
growth assay were performed with indicated conditions. Plates were incubated at 










Figure 3.10. H90A has dominant-negative effects on CeHRG-1 function in C. 
elegans. (A) The rescue plasmid Phrg-1::HRG-1-HA::ICS::GFP was constructed by 
recombining the putative hrg-1 promoter (~3 kb upstream of hrg-1 gene, Phrg-1), the 
fused hrg-1 gene (HRG-1-HA::ICS::GFP) and the 3’-UTR of hrg-1 gene into a single 
destination vector, pDEST-R4-R3, and was bombarded into the hrg-1hrg-4unc-
119 strain to generate hrg-1 transgenic worms. hrg-1 transgenic worms were 
synchronized, placed on NGM plates seeded with RP523 bacteria grown at 50 μM 
hemin (P0), synchronized again and transferred to RP523 plates of low (1 μM) and 
high (50 μM) hemin (F1) and the growth followed for two subsequent generations. 
Representative images of F1 and F2 progeny are shown. Scale bar, 50 μm. (B) The 
sizes of worms in (A) were measured by COPAS BioSort. Time of flight (TOF) 
indicate the length of worms, n>200. (C) Worms were grown as described in ΔhemB 
growth assay. Approximately 100 worms/well of F1 worms were transferred to 12-
well plates, inoculated in mCeHR-2 medium supplemented with 1.5 M hemin 
chloride and 10 M of ZnMP for 16 hours. ZnMP fluorescence intensity was scored 
by a DMIRE2 epifluorescence microscope (Leica). (D) The mean fluorescence 
intensities of ZnMP in (C) were quantified by SimplePCI, n=50. (E) Worms were 
grown as described in ΔhemB growth assay. F1 worms were harvest at young gravid 
stage from ΔhemB plates, washed twice with M9 buffer, resuspended in lysis buffer 
with protease inhibitor cocktail set III and Lysing Matrix D beads, and disrupted 
using FastPrep-24 (MP Bio) for 60s at the 6.5 m/s setting. The total protein 
concentration of worm lysates was quantified with the Bradford reagent (Bio-Rad) 









heme, which might be due to the modest phenotype of the Δhrg-1Δhrg-4 double 
mutant strain. However, expression of the H90A mutant exhibited a severe growth 
arrest phenotype in the F1 progeny of Δhrg-1Δhrg-4 worms fed with RP523 grown 
with 2 μM heme compared to the vector or wild-type control.  This growth phenotype 
was fully suppressed with 50 μM heme (Fig. 3.10A, B). This result suggests that in 
addition to being a dysfunctional heme transporter, as revealed in the yeast growth 
assay, the H90A mutant exerts a dominant negative effect that’s observable only at 
low heme.  
To further investigate heme transport mediated by CeHRG-1 in C. elegans, 
we measured ZnMP uptake in these transgenic worms. From our previous RNAi 
results [58], we expected that worms expressing CeHRG-1 or the H88A mutant 
would have reduced fluorescence signal in Δhrg-1Δhrg-4 double mutant background, 
as they can disperse the vesicular accumulated ZnMP into the cytosol; and expression 
of the H90A mutant would have equal or increased ZnMP signal comparing to vector, 
as H90A is a non-functional or dominant-negative heme transporter. Surprisingly, as 
for the wild-type, the H90A mutant transgenic worms also showed reduced ZnMP 
fluorescence signal (Fig. 3.10C, D).  Because HRG-1-related proteins are multimeric, 
we speculate that the reduced ZnMP fluorescence concomitant with growth 
retardation could be because the H90A mutant may hetero-multimerize with other 
HRG-1 paralogs and thus disrupt heme import into the intestine.  Recent studies 
showed the H32R mutation in ferroportin (FPN1) has a dominant negative effect in 
the flatiron mouse [150]. This is because the H32R mutant multimerizes with the 




preventing iron export.  Indeed, immunoblotting results show that, unlike wild-type 
CeHRG-1 or H88A mutant, the H90A mutant migrates primarily as a monomer, 
raising the possibility that it has the potential to interfere with multimerization of 
other HRG-1 paralogs (Fig. 3.10E). 
 
A Conserved Histidine in TMD2 is Essential for Heme Transport by Human 
HRG-1   
The human homolog of HRG-1-related proteins is only ≈20% identical to 
CeHRG-1 even though worm and human proteins colocalize to the endolysosomal 
compartment, and bind and transport heme, implying that these proteins are 
functional orthologs [58]. To verify whether the results of our mechanistic studies of 
worm HRG-1-related proteins can be extended to humans, we expressed hHRG-1 in 
hem1Δyeast. Immunoblotting of lysates from yeast cells expressing hHRG-1-HA 
revealed hHRG-1 migrating at the predicted molecular weight, albeit the steady-state 
protein level was significantly lower than CeHRG-1 and CeHRG-4 (Fig. 3.11B). To 
optimize the expression of hHRG-1 in yeast, we generated a synthetic open-reading 
frame (yhHRG-1) which was modified for codon usage bias; the Codon Adaptation 
Index (CAI) was upgraded from 0.51 to 0.90 for maximal expression in S. cerevisiae. 
Steady state proteins levels for optimized yhHRG-1-HA were at least ten-fold greater 
than the unoptimized hHRG-1-HA (Fig. 3.11B). This difference in expression was 
concomitant with the significantly greater ability of yhHRG-1-HA to rescue the 




compared to vector control), stimulate Fre1p enzymatic activity, and induce 
CYC1::lacZ reporter activity (Fig. 3.11D-F). Indirect immunofluorescence 
microscopy indicated that similar to CeHRG-1, the human homolog also localized 
primarily to the yeast vacuole (Fig. 3.11C). Despite low identity at the amino acid 
sequence level between the human and worm proteins, several features are 
remarkably conserved in HRG-1-related proteins. Namely, both homologs localized 
to similar endocytic compartments, showed similarity in four predicted TMDs, and 
possess conserved amino acids that were topologically preserved. Potential ligands at 
the corresponding position in hHRG-1 were H56 in TMD2, H100 in the E2 loop, and 
YAHRY in the C-terminus (Fig. 3.11A). As proof-of-principle, we generate a H56A 
mutant in hHRG-1. The mutant protein expressed and localized to the vacuole but had 
significantly reduced function consistently in all three assays irrespective of heme 
concentrations (Fig. 3.11B-F). These results strongly support our proposition that the 
overall mechanism for heme transport by HRG-1-related proteins is likely conserved 
between worms and humans.  
In collaboration with Dr. Mark Fleming at Harvard Medical School, we have 
identified a C to T single base variant (pt EA023) of the human HRG-1 gene in 
African American population, which results in a P36L substitution in the E1 
exoplasmic loop between TMD1 and TMD2 (Fig. 3.11A). The individuals 
heterozygous for P36L are anemic (Unpublished observations). Although the 
possibility that those patients are compound heterozygous with polymorphisms in 
other genes cannot be excluded, our yeast growth assay indicated the P36L variant 




3.12). This result suggests the P36L substitution in hHRG-1 results in a dysfunctional 
protein and consequently anemia due to either haploinsufficiency or a dominant 
negative effect. Furthermore, our previous work has shown moderate knockdown of 
HRG-1 in zebrafish leads to mild anemia (MO1), while severe depletion causes 
lethality and growth defects (MO2), suggesting that lowering the expression of HRG-
1 can directly result in anemia (8). To evaluate whether additional human 
polymorphisms in HRG-1 caused a reduction in heme transporter activity, we 
searched the NHLBI Exome Sequencing Project (ESP) and found three variants, 
G73S, S82L and W115C. In contrast to P36L, these variants were only present in 
European Americans (0.0309%, 0.0309% and 0.0279%, respectively) but not in 
African Americans. Interestingly, P36 and W115 are highly conserved residues in 
vertebrates, whereas G73 and S82 seem to be dispensable (Fig. 3.12A). Yeast growth 
assay indicated an inability of the W115C variant to transport heme, while G73S and 
S82L had no obvious effect on hHRG-1 heme transport activity (Fig. 3.12B).  In the 
future, it would be important to evaluate whether these hHRG-1 variants can rescue 
the anemia phenotype in zebrafish hrg-1 morphants. 
We next determined whether the assays employed to determine the heme 
import function of hHRG-1 can be extended to FLVCR2, another transporter recently 
postulated to be a heme importer in human cells [65]. hFLVCR2 was abundantly 
expressed in hem1Δ yeast, localized primarily to the plasma membrane and 
intracellular vesicles (Fig. 3.12 A, B). Yeast expressing hFLVCR2 showed 2-fold 
increase in ferrireductase activity, indicating elevated heme in the secretory pathway 




Figure 3.11. Heme transport analysis of wild-type and mutant hHRG-1. (A) 
Putative topology of hHRG-1 predicted by TMHMM 2.0 and SOSUI. The amino and 
carboxyl-termini are cytoplasmic, C1 is the cytoplasmic loop and E1 and E2 are the 
exoplasmic loops. Potential heme interacting residues are shaded in red. (B) 
Immunoblotting was performed on transformants overexpressing c-terminus HA 
epitope tagged hHRG-1 or yeast codon-optimized yhHRG-1 and its H56A mutant 
(yH56A-HA) in the hem1Δ(6D) strain. Predicted molecular mass of hHRG-1 was 
detected as indicated by filled circles. The endogenous expression level of 
phosphoglycerate kinase 1 (PGK1) was used as loading control (30 μg total protein / 
lane). (C) Immunofluorescence microscopy results of yhHRG-1-HA and yH56A-HA 
mutant in the hem1Δ(6D) strain. Rabbit anti-HA was used as the primary antibody, 
and an AlexaFluo568-conjugated goat antirabbit antibody was used as the secondary 
antibody. Scale bar, 5 μm. (D) The hem1Δ(6D) strain was transformed with empty 
vector pYES-DEST52, hHRG-1 and its mutants. Spot growth assay were performed 
with indicated conditions. Plates were incubated at 30°C for 3 days prior to imaging. 
(E) The hem1Δ fre1Δ fre2Δ MET3-FRE1 strain was transformed with empty vector 
pYES-DEST52, hHRG-1 and its mutants. Ferric reductase assay were performed with 
indicated concentrations of hemin. Ferric reductase activity (nmol / 106 cells / min) 
was measured and normalized to the activity of vector. (F) The hem1Δ(6D)) strain co-
transformed with pCYC1-LacZ and empty vector pYES-DEST52, CeHRG-1 or its 
mutants. β-galactosidase activity was measured. Error bars represent the standard 
error of the mean (SEM) from three independent experiments. * p < 0.05, ** p < 0.01, 









Figure 3.12. Heme transport analysis of hHRG-1 variants. (A) Multiple sequence 
alignment of vertebrate HRG-1 orthologues. Asterisks indicate polymorphic positions 
in human HRG-1.   (B) The hem1Δ(6D)  strain transformed with empty vector pYES-
DEST52, hHRG-1-HA and hHRG-1 variants identified in human population. Spot 
growth assay were performed with indicated conditions. Plates were incubated at 







Figure 3.13. Overexpression of hFLVCR2 did not increase heme uptake in yeast 
hem1Δ strain. (A) Immunofluorescence microscopy results of hFLVCR2 in the 
hem1(6D) strain. Rabbit anti-HA was used as the primary antibody, and an 
AlexaFluo568-conjugated goat anti-rabbit antibody was used as the secondary 
antibody. Scale bar, 5 µm. (B) Immunoblotting was performed on transformants 
overexpressing c-terminus HA epitope tagged CeHRG-4, CeHRG-1 or hFLVCR2 in 
the hem1(6D) strain. Predicted molecular mass were detected as indicated by filled 
circles (15 µg / lane). (C) The hem1Δfre1Δfre2ΔMET3- FRE1 strain was transformed 
with empty vector pYES-DEST52, CeHRG-4, CeHRG-1 and hFLVCR2. Ferric 
reductase assay were performed with indicated concentrations of hemin. Ferric 
reductase activity (nmol / 106cells / min) was measured and normalized to the activity 
of vector. (D) The hem1Δ(6D)  strain transformed with empty vector pYES-DEST52, 
CeHRG-4, CeHRG-1 and hFLVCR2. Spot growth assay were performed with 
indicated conditions. Plates were incubated at 30°C for 3 days prior to imaging.   
Error bars represent the standard error of the mean (SEM) from three independent 











hem1Δ yeast compared to vector, even at 10 μM heme (Fig. 3.13D). These results 
suggest that, under our assay conditions, hFLVCR2 does not function as a plasma 
membrane heme importer. 
 
C-terminal chimeras of HRG-1-related proteins reveal structures required for 
localization 
Both CeHRG-1 and hHRG-1 proteins have predicted tyrosine and acidic 
dileucine based sorting motifs on their C-terminal regions (Fig. 3.14A). The YxxØ 
motif is involved in rapid internalization of the proteins from the plasma membrane. 
This sorting motif has also been implicated in the targeting of transmembrane 
proteins to the lysosomes and sorting of proteins to the basolateral membrane in 
polarized cells [151]. The dileucine-based sorting signal plays an important role in 
sorting a number of type I, type II, and multispanning membrane proteins. Like the 
tyrosine motif, the D/ExxLL motif is also involved in the internalization of proteins 
from the plasma membrane and targeting of proteins to the lysosomes. Furthermore, 
our protease protection assays indicated that the C-terminus of HRG-1-related 
proteins is cytoplasmic (unpublished observations).  
 
In order to systematically identify the portion of HRG-1 dictating localization 
from function, we synthesized several fusion chimeras by swapping the N and C 
terminal segments of HRG-1-related proteins (Fig. 3.14B) and examined their 




Figure 3.14. Topology of N- and C-terminal chimera constructs of CeHRG-1, 
CeHRG-4 and hHRG-1.  (A) Predicted topology of CeHRG-4, CeHRG-1, hHRG-1 
with residues essential to heme transport marked in grey, tyrosine sorting motifs in 
red and dileucine motifs in blue. (B) Schematic of chimera constructs. CeHRG-1 is 
shown in blue, CeHRG-4 in green, and hHRG-1 in red. The transmembrane domains 
for each are indicated by rectangles. The chimeras of CeHRG- 1, CeHRG-4, and 












are summarized in Appendix IV. In short, when the C-terminus of CeHRG-1 was 
replaced with the C-terminal domain of CeHRG-4, CeHRG-114-CFP was seen on the 
plasma membrane of HEK293 cells, consistent with the localization of CeHRG-4-
CFP.  Conversely, CeHRG-441-CFP, a construct generated by replacing the C-
terminal domain of CeHRG-4 with the CeHRG-1 C-terminal domain, localized to the 
endosomal-lysosomal membranes as CeHRG-1-CFP. C-terminal domain chimeras of 
hHRG-1 and CeHRG-4 exhibited similar results. By contrast, swapping neither the 
N-terminal domains nor the transmembrane domains of HRG-1-related proteins 
changed their membrane localization. Similarly, when expressed in polarized MDCK 
II cells, CeHRG-4-CFP localized to the apical surface whereas CeHRG-1-CFP and 
hHRG-1-CFP were detected in vesicular compartments immediately underneath the 
apical surface. Swapping the C-terminal domains of these proteins resulted in an 
equivalent exchange of the localization of each chimeric protein. These findings 
indicate that the C-terminal domains of HRG-1-related proteins dictate proper 
intracellular localization and trafficking.  
 
HRG-1 chimeras show heme transport activity 
In order to correlate the intracellular localization of these chimeras with heme 
transport activity, we exploited the previously established functional assays in yeast 
[129,130]. HRG-1-related proteins transport heme thereby rescuing the growth of the 
hem1Δ yeast strain, a heme auxotroph, at low heme concentrations [152]. hem1Δ 




protein C-terminal chimeras showed growth that were comparable to wild-type HRG-
1-related proteins. However, yeast transformed with CeHRG-411-HA, CeHRG-1ΔN-
HA and hHRG-1ΔN-HA showed significantly decreased growth at 0.25 μM heme 
compared to wild-type CeHRG-1-HA and hHRG-1-HA (Fig. 3.15). These studies 
indicated that although the N-terminal domains of CeHRG-1 or hHRG-1 may not 
affect localization, they play an essential role in the heme transport function of these 
proteins. To further assay the effect of these chimeras on the regulatory pool of 
cytoplasmic heme, we performed β-galactosidase activity assays using the CYC::lacZ 
promoter-reporter fusion. As previously reported, wild-type HRG-1-related proteins 
transformed yeast show increased β-galactosidase activity compared to yeast 
transformed with the pYES-DEST52 empty vector [152]. Yeast transformed with C-
terminal chimeras also showed a significant increase in LacZ activity compared to 
vector, similar to the changes observed in the growth of hem1Δ transformed yeast 
(Fig. 3.16). We observed a lack of activity for the CeHRG-1ΔN-HA, and a more 
modest decrease in β-galactosidase activity of the CeHRG-411-HA chimera and 
hHRG-1ΔN-HA. The decreased activity observed in these N-terminal chimeras can 
not be solely explained by protein degradation because the expression of CeHRG-
411-HA is much higher than wild-type CeHRG-1-HA in yeast (Fig. 3.17). Taken 
together, these studies revealed that the N-terminal domains might be essential for 
HRG-1 heme uptake function.  
Analysis of the N-terminal domain revealed that although it does not affect the 
localization of HRG-1-related proteins, it is necessary for the function of CeHRG-1. 




Figure 3.15. N-terminal chimeras of worm and human HRG-1 have impaired 
heme transport activity in hem1Δ S. cerevisiae. hem1Δ yeast cells were 
transformed with pYES-DEST52 (vector), HA-tagged wild-type HRG-1-related 
proteins and domain-swapping chimeras. Expression of all C-terminal and 
transmembrane domain chimeras rescued hem1Δ growth, similarly to what was seen 
with the wild-type proteins. Yeast cells transformed with CeHRG-411-HA, CeHRG-











Figure 3.16. The N-terminus is required for CeHRG-1 transport heme in yeast. 
β-galactosidase activity was assayed in yeast cells co-transformed with pCYC-LacZ 
and pYES-DEST52 (vector), CeHRG-1-HA, CeHRG-4-HA or the chimeras listed. 












































































































































































































































Figure 3.17. CeHRG-1 and CeHRG-4 chimeras show varied multimeric 
patterns. (A) HEK293 cells were transfected with CeHRG-1-HA, CeHRG-4-HA  
and chimeras, and analyzed by immunoblotting for the C-terminal HA tag. (B) 
Immunoblot of HRG-1 chimeras expressed in hem1Δ yeast strain, analyzed by 
immunoblotting for the C-terminal HA tag.  Phosphoglycerate kinase 1 (PGK1) was 












regulating protein-protein interactions such as HRG-1 multimerization.  To further 
delineate the N-terminal domains’ specific role in heme uptake, we examined the 
multimeric patterns of chimeras in mammalian and yeast cells. Interestingly, chimeras 
with the N-terminal domain of CeHRG-4 (CeHRG-441, 411 and 414) migrated as 
higher molecular weight multimers that was comparable to wild-type CeHRG-4, 
whereas chimeras with the N-terminal domain of CeHRG-1 (CeHRG-114, 144 and 
141) migrated as wild-type CeHRG-1 oligomers (Fig. 3.17). These results indicate 
that the N-terminal domains of HRG-1-related proteins might be essential for protein 
folding or multimerization. Thus, the decreased heme transport activities of CeHRG-
1ΔN-HA, CeHRG-411-HA and hHRG-1ΔN-HA observed in yeast assays could be a 
consequence of aberrant multimerization and/or lower protein stability. 
 
DISCUSSION 
Our genetic studies in worms reveal a definitive growth phenotype only when 
both hrg-1 and hrg-4 are deleted (Fig. 3.1C and D). Results from the hem1Δ yeast 
growth assays clearly demonstrate that, in addition to CeHRG-1 and CeHRG-4, two 
additional paralogs exist for heme transport in C. elegans. This is not surprising given 
that worms are solely dependent on environmental heme for growth and development. 
Thus, multiple backup systems exist in worms that ensure adequate heme is acquired 
for sustenance and transfer to their progeny [73]. From an experimental standpoint, 
these backup systems, however, occlude a thorough mechanistic analysis of HRG-1-




worms, we exploited the hem1Δ yeast strain which is unable to synthesize heme and 
lacks the ability to utilize exogenous heme at low concentrations. In the current study, 
we employed independent functional assays in yeast to probe the molecular 
characteristics of heme transport by HRG-1- related proteins [130]. Our results reveal 
that, despite sharing only 27% identity and localizing to different subcellular 
compartments, the overall mechanism for heme transport employed by CeHRG-1 and 
CeHRG-4 are similar. We attribute the greater activity of CeHRG-4 in utilizing 
exogenous heme in the yeast reporter assays to its plasma membrane localization. By 
contrast, although CeHRG-1 predominantly localizes to the vacuolar membrane, it 
still has significant ability to utilize exogenous heme. It is conceivable that, as 
observed in mammalian cells [58], a portion of CeHRG-1 traffics to the plasma 
membrane.  
Based on data from our assays, we propose a mechanistic model for heme 
import by HRG-1-related proteins. A histidine in the E2 loop on the 
extracellular/luminal side binds and transfers heme to a histidine (or a tyrosine at the 
synonymous position in CeHRG-4) in TMD2 within the channel. The heme is 
subsequently translocated to the cytoplasmic side facilitated by the FARKY (YAHRY 
in humans) motif in the C-terminal tail. The aromatic and positively charged amino 
acids in this motif may serve as heme ligands and stabilize or orient the vinyl and 
propionic acid side chains. A precedent for such a mechanism was recently 
established for the Helicobacter hepaticus CcsBA, a multi-pass ten transmembrane 
channel [153]. Heme is transported from the cytoplasm into the bacterial periplasm 




weak heme binding site within the TMDs, followed by translocation to a periplasmic 
heme binding region comprising two histidines and a WWD domain [153]. This 
mechanism of heme transfer prevents oxidation of the heme-iron and allows for 
proper orientation of the heme for covalent bond formation with the reduced 
apocytochrome. Our previous studies show that HRG-1-related proteins migrate as 
dimers and trimers on nondenaturing PAGE, raising the possibility that HRG-1-
related protein functions as a multimer [58]. Thus, optimal transport function may be 
dependent on the cumulative contribution from individual heme-binding ligands from 
each subunit. Such a situation is observed with the three TMD copper transporter Ctr1 
which functions as a symmetric trimer to form a channel lined with ligands for copper 
binding and transport [154].  
Based on the degree of functional rescue in the yeast reporter assays for each 
mutant of the HRG- 1-related proteins, we postulate that a hierarchy may exist for 
binding heme amongst the ligands. HRG-1-related proteins may contain dual binding 
sites or heme translocation: a weak low affinity site followed by a high affinity 
primary substrate binding site. This concept is supported by the recent crystal 
structure of the LeuT leucine transporter and biochemical characterization of CcsBA 
heme transporter [153,155,156,157]. Both proteins possess a low affinity, transiently 
occupied substrate binding site that works in conjunction with a high affinity primary 
binding site to promote substrate movement and conformational gating.  
Site-directed mutation reveals that H90 in CeHRG-1 (H56 in hHRG-1) is 
replaced by a synonymous Y63 in CeHRG-4 in TMD2. Although both His and Tyr 




decreases the reactivity of heme possibly because of the increased anionic character 
of the phenolic group in Tyr which preferentially stabilizes oxidized heme (ferric and 
ferryl-oxo) [148,149]. Primary amino acid sequence alignments of putative HRG-1-
related proteins from other species reveal that the His in TMD2 is highly conserved in 
the majority of species examined. However, in a small number of HRG-1 homologs, 
the His is substituted by a Tyr, as in the case of the HRG-1 homolog from the human 
pathogen Leishmania amazonensis which functions as a heme transporter [120]. C. 
elegans is a heme auxotroph and must acquire heme from the environment to sustain 
growth and development. Under physiological conditions, this soil-dwelling 
bacterivorous nematode likely ingests heme from multiple sources to maximize heme 
utilization through the concerted actions of both, CeHRG-1 and CeHRG-4 in the 
worm intestine. In its natural habitat, CeHRG-4 on the intestinal plasma membrane 
might encounter oxidized heme more readily than CeHRG-1 which might transport 
heme derived from the digestion of ingested hemoproteins in the lysosome, an 
organelle equivalent to the yeast vacuole, a storage compartment for iron, and 
plausibly, heme [158,159].  
What drives translocation of heme through the HRG-1-related transporters? 
One possible mechanism could be heme concentration gradients generated by 
interactions of the transporter with downstream binding partner(s). In Gram positive 
bacteria, heme transfer from IsdA to IsdC, cell-wall anchored proteins in 
Staphylococcus aureus, is driven by kinetics and transient stereospecific weak 
“handclasp” interactions [160,161]. This is in stark contrast to Gram negative bacteria 




[143,144,162]. Another mechanism could involve coupling with an energetically 
favorable flow or counterflow of ion gradients generated by primary transporters, a 
feature characteristic of permeases. Indeed, a recent study demonstrated that human 
HRG-1 associates with the V-ATPase proton pump [60], suggesting the possibility 
that a proton gradient generated by V-ATPases may drive heme transport, similar to 
the endocytic calcium transporters in yeast [163].  
Is the mechanism for heme transport by HRG-1-related proteins shared with 
other metazoan heme transporters? FLVCR2, a member of the major facilitator 
superfamily, was recently reported to import heme in mammalian cells [65]. 
Although we did not observe heme import in our assay conditions, given the high 
degree of homology between FLVCR2 and the heme effluxer FLVCR1 [62,164,165], 
it is possible that FLVCR2 may export heme. This explains the increased 
ferrireductase activity observed in yeast expressing FLVCR2. As an effluxer, 
FLVCR2 should transport heme to the luminal side of the intracellular compartments. 
Thus the secretory pathway had elevated heme, even though the heme content was 
decreased in whole cell. These results with FLVCR2 are similar to our unpublished 
results with MRP-5, a heme exporter identified in C. elegans. Hemopexin facilitates 
heme export by FLVCR1 by binding to a 69 amino acid peptide (residues 132-201), 
which contains two exoplasmic loops and two TMDs [166]. In silico examination of 
the membrane topology of FLVCR2 predicts a 12 TMD protein with several 
strategically placed, evolutionarily conserved, heme-binding ligands in the 
exoplasmic and cytoplasmic loops and within the TMDs. Genetic studies have 




null mice lack definitive erythropoiesis and are embryonic lethal [63]. A structure-
function analysis of FLVCR heme transporters will lay the groundwork for 
establishing whether the overall mechanism for heme transport identified for HRG-1-
related proteins is also conserved in FLVCR. Although the physiological role for 
heme import by hHRG-1 in humans is still unclear, concurrent genetic studies with 
the mouse equivalent of Hrg-1 will shed significant insight on the biological role of 
heme transporters in mammalian growth and development. 
In addition to the functional residues we identified that are critical for heme 
transport, non-canonical tyrosine and dileucine based sorting motifs were indentified 
in both CeHRG-1 and hHRG-1 (Fig. 3.14). These motifs determine internalization 
and sorting to endosomal-lysosomal vesicles within the cytoplasm [151]. FPP assays 
revealed the C-terminal domains of HRG-1-related proteins indeed reside in the 
cytoplasm. Furthermore, swapping the C-terminal domains of CeHRG-1 or hHRG-1 
with CeHRG-4 resulted in reversal of protein localization. Our studies revealed 
plasma membrane localization for CeHRG-114-GFP and endo-lysosomal localization 
for CeHRG-441. These findings indicate that the C-terminal domains of CeHRG-1, 
CeHRG-4 and hHRG-1 are required for proper protein localization. The sorting 
motifs identified in the cytoplasmic C-terminal domains of CeHRG-1 and hHRG-1 
likely play a role in protein retrieval and sorting to the endolysosomal compartments. 
Further studies will be required to determine how and what regulates the intracellular 
localization of HRG-1-related proteins, and how this is tied to their function in C. 








Neglected tropical diseases (NTDs) infect approximately 1.4 billion of the 
world's population, mainly in underdeveloped countries. NTDs are a group of 13 
parasitic and bacterial infections, in which >90% infections are caused by a diverse 
group of parasitic worms or Trypanosomatids [167,168,169,170]. However, due to 
the lack of research funding support and general genome complexity compared to 
those of model organisms, little progress has been made in developing effective 
treatment agents [171,172]. To sustain their growth and reproduction, parasites 
exhibit distinct adaptations that allow them to acquire nutrients unidirectionally from 
the host.  An example is the heme acquisition pathway exploited by Trypanosomatid 
and helminth parasites, suggesting a unique antiparasitic clinical target 
[13,14,118,120].   
We have identified HRG-1 and HRG-4 as the first heme 
importers/transporters using the genetically tractable organism C. elegans [58]. 
Subsequent analysis of human and Leishmania HRG-1 orthologs revealed conserved 
pathways for cellular heme trafficking across species [120]. Currently, there are no 
pharmacological tools to aid in the study of the cellular and physiological roles of 
these eukaryotic heme transporters. Here, we report the development and validation 




molecule antagonists of HRG-1-related proteins using a simple growth assay in yeast. 
Because parasitic nematodes and the kinetoplastids also acquire heme from the 
environment, it is anticipated that compounds identified in this screen can be used to 
establish the feasibility of targeting the heme transport pathway for the treatment of 
helminth infections, Trypanosomiasis, intestinal nematodes, kinetoplastid diseases, 
lymphatic filariasis, onchocerciasis, and Leishmaniasis, as well as human genetic 
disorders of heme and iron metabolism. 
 
Results 
HRG-1-related proteins transport the toxic heme analog GaPPIX in wild-type 
yeast 
We have utilized yeast as a model to investigate HRG-1-mediated heme 
uptake. Growth of the heme deficient yeast strain hem1Δ can be rescued by 
expressing HRG-1-related proteins in the presence of low heme [152]. We further 
revealed that ectopic expression of HRG-1-related proteins confers uptake of not only 
heme, but also heme analogs, in yeast. As shown in Fig. 4.1A, wild-type yeast 
expressing either HA-tagged or untagged CeHRG-4 are extremely sensitive to the 
toxic heme analog, gallium protoporphyrin IX (GaPPIX). Dose-response growth 
curves demonstrate that CeHRG-4-expressing yeast have >2,000-fold lower relative 
IC50 (half maximal inhibitory concentration) value for GaPPIX than yeast 
transformed with the vector alone (Fig. 4.1B). Because gallium cannot undergo 




Figure 4.1. HRG-4 transport the toxic heme analog GaPPIX in wild-type yeast. 
(A) Transformed wild-type w303 yeast were serially diluted and plated on 2% 
raffinose SC (-Ura, +0.4% galactose) plates supplemented with no or 1µM GaPPIX to 
determine growth after 3 days.  (B) Transformed wild-type w303 yeast cells were 
inoculated at 0.1 OD600 in 10 mL of 2% raffinose SC (-Ura, +0.4% galactose) 
medium and the indicated concentrations of GaPPIX, 30ºC with shaking at 225rpm 
for 16h prior to determining growth. The relative IC50 (mean ± SEM) for Vector was 









hemoproteins is cytotoxic [15]. As we have demonstrated in C. elegans, GaPPIX 
toxicity in HRG-4 expressing yeast can be alleviated by addition of excess heme 
which effectively competes with GaPPIX for uptake [58]. 
 
High-throughput screen development 
To identify small molecule antagonists of the HRG-1 heme transporters in an 
HTS-compatible format, a simple yeast growth assay was developed based on the 
observation that ectopically expressed HRG-1-related proteins confers uptake of 
heme and the toxic heme analog, GaPPIX in yeast. To avoid additional steps of yeast 
transformation and consequent data variation, yeast strains stably integrated with 
HRG-1-related proteins were generated. Putative HRG-1-related proteins antagonists 
are easily identified when the lethality of GaPPIX on yeast growth is blocked as 
assessed by optical absorbance (Fig. 4.2). 
To develop a robust and reproducible protocol for the HTS assay in 384-well 
plate format, various control parameters including yeast density and incubation time,  
well volume, sealing methods, humidification, shaking effect and GaPPIX 
concentration needed to be optimized. For CeHRG-4 expressing yeast cells, adding 
0.3 μM or 1 μM GaPPIX was sufficient to fully inhibit cell growth (Fig. 4.3). High 
concentrations of GaPPIX (≥ 30 μM) occasionally precipitated, an effect exacerbated 
by shaking. We used 1 μM GaPPIX in the HTS for identification of the CeHRG-4 
antagonists. Standard growth curves of other worm HRG-1 paralogs were performed 
using the optimized conditions. Because CeHRG-1 is primarily localized to the 




circumvent this problem, we utilized the plasma membrane CeHRG-1 chimera, 
CeHRG-414, as a substitute (Fig. 4.3).  Yeast expressing each of the four worm 
HRG-1 paralogs was sensitive to GaPPIX toxicity, permitting us to potentially 
identify small molecule antagonists which may have transporter selectivity and aiding 
in chemically dissecting the significance of redundant heme transporters in C. 
elegans. 
Although the compounds in the chemical library were dissolved in DMSO, 
under the assay conditions, 1% DMSO had negligible effects on cell growth and was 
consequently chosen as the negative control (Fig. 4.3). We next evaluated two 
positive controls: (1) Addition of excess heme to compete with GaPPIX for uptake by 
CeHRG-4.  Heme did not fully restore cell growth due in part to the toxicity of excess 
heme itself and the propensity of heme/GaPPIX to precipitate at high concentrations 
(Fig. 4.4). To prevent heme aggregation, several solvents were tested, including 0.3N 
NH4OH (pH 8.0), DMSO, 20 or 40 mM MES buffer (pH 6.1) and 0.05% Tween 20, 
though none of the solvents provided significant improvement. (2) Alternatively, 
0.4% glucose (dissolved in DMSO) was used to suppress expression from the GAL1 
promoter driving CeHRG-4 expression.  Though this control does not mimic the 
mechanism of rescue we sought, cell growth was fully restored (Fig. 4.4). 
To test whether the optimized assay parameters could be scaled for HTS, a 
series of experiments were performed to evaluate signal-to-background ratio, 
variation within and between plates, and day-to-day effects by applying the statistical 




Figure 4.2. Schematic illustration of assay development and readouts. (A) Wild-
type yeast can synthesize heme but utilizes exogenous heme poorly. Therefore, yeast 
cells are resistant to the toxic heme analog, GaPPIX. (B) Ectopic expression of 
CeHRG-4 confers uptake of GaPPIX, prohibiting yeast growth in microtiter plates. 











Figure 4.3. Standard yeast growth curves of worm HRG-1 paralogs. Yeast cells 
expressing CeHRG-4, CeHRG-414, CeHRG-5 or CeHRG-6 were grown to stationary 
phase. Yeast were plated at OD600 = 0.05 in growth medium (70 µl/well; 384 
wells/plate) containing increasing concentrations of GaPPIX. The assay plates were 
then incubated without shaking in a humidity container at 30ºC. OD600 values were 












and suitability for a high-throughput setting. An assay that has a Z’ factor between 0.5 
and 1.0 is considered as an excellent assay for use in a full-scale, high-throughput 
screen. Following the procedure depicted in Fig. 4.5, three independent trial 
experiments were performed in triplicate on different days. All of the assay plates had 
a Z’ factor of > 0.8 across individual plates, between plates, and between experiments 
(Table 4.1). A mock experiment of 30 total plates was also performed which showed 
an average Z’ value of 0.815 (Table 4.2). These results confirmed that our assay is 
now suitable to be advanced into HTS. 
 
High-throughput screen to identify antagonists of parasitic HRG-1-related 
proteins 
The free-living nematode C. elegans and related parasitic nematodes do not 
synthesize heme [15].  Until recently, it was thought that all organisms synthesized 
heme with little variation via a well-defined pathway. We found, however, that C. 
elegans lacks the heme biosynthetic pathway enzymes [15].  It depends entirely upon 
diet for its heme and incorporates the ingested heme in toto into numerous 
hemoproteins involved in key biological reactions.  Worms are growth-arrested in the 
presence of inadequate heme, but high levels of heme are toxic.  Thus, these 
organisms must carefully control intracellular heme levels to survive.  In fact, an 
analysis of publicly available helminths sequence databases revealed that obvious 
orthologs to heme biosynthesis pathway enzymes are absent [15].  A biochemical 




activity for the heme synthesis pathway [15]. These measurements support the idea 
that C. elegans and parasitic nematodes of animals and, possibly, plants may have 
similar heme transport and assimilation pathways since none of them make heme but 
all contain hemoproteins.  
As observed for parasitic helminths, Trypanosomatids such as Leishmania 
acquire their heme from the environment/host.  In collaboration with Dr. Norma 
Andrews’ laboratory on the UMD campus, we identified and cloned Leishmania 
LHR-1, the homolog of CeHRG-4.  L. amazonensis promastigotes cultured in a heme 
deficient growth medium resulted in the upregulation of LHR-1 mRNA expression 
[120].  As was demonstrated with CeHRG-4, LHR-1:GFP was also found to localize 
to the plasma membrane and HA epitope tagged LHR-1 fully rescued the growth 
defect phenotype of the yeast hem1 heme-defective mutant [120].  These results 
confirm that LHR-1 and CeHRG-4 are homologous heme transporters.   
The major advantages of Leishmania over helminths are (a) single celled 
protozoa versus a multi-cellular nematode, (b) fully sequenced and annotated 
genome, (c) ease of growth in ex vivo cell culture or in vivo in mice, (d) genetically 
tractable to overexpress or knockout genes, and (e) no current drugs available except 
antimonials which are highly toxic to humans.  The Leishmania LHR-1 is therefore a 
prototypical parasite heme transporter for a HTS to identify antagonists because of 





Figure 4.4. Evaluation of positive controls. CeHRG-4 yeast incubated with 0.3 µM 


































0.3M / 1M GaPPIX
Ga + 0.4% glucose
Ga + 0.3M heme
Ga + 1M heme
Ga + 3M heme
Ga + 10M heme








Table 4.1 Plate effect statistics 
  Z’ score 




















Table 4.2 Mock experiment statistics 
Plate# Z’ score Plate# Z’ score Plate# Z’ score 
1 0.821 11 0.801 21 0.784 
2 0.801 12 0.833 22 0.840 
3 0.806 13 0.849 23 0.812 
4 0.825 14 0.821 24 0.809 
5 0.834 15 0.825 25 0.823 
6 0.874 16 0.734 26 0.842 
7 0.795 17 0.792 27 0.825 
8 0.829 18 0.749 28 0.812 
9 0.844 19 0.794 29 0.848 





Figure 4.5. Outline of HTS assay procedure. Yeast integration lines were streaked 
on 2% w/v raffinose SC –His plate from -80°C glycerol stocks, and incubated at 30°C 
for 3 days until colonies with pink color formed. The day before adding the 
compounds, 10 to 20μL of yeast cells were collected from the plate and inoculated in 
50mL 2% w/v raffinose SC –His liquid medium at 30°C, with shaking at 250rpm for 
24 to 30 hours. To prepare the assay culture, 2% w/v raffinose SC (–His, +0.4% 
galactose) medium supplemented with 2 to 20μM GaPPIX was loaded into 384-well 
plates(Nunc), 35μL/well using a Multidrop reagent dispenser (TiterTek). The plates 
were then loaded with 0.7μL compound/well using robotic liquid handlers 
(Beckman). Yeast cells were prepared by centrifuging the overnight liquid culture at 
3,000g for 5min and resuspending in 2% w/v raffinose SC (–His, +0.4% galactose) of 
an OD600 = 0.1. 35μL/well of yeast culture was added to the preloaded 384-well plates 
using Multidrop and incubated in a humidity container at 30°C without shaking. After 









In addition to LHR-1, we also identified and assembled HRG-1 orthologs 
from an additional 34 published parasite genomes, ranging from human, companion 
animal or cattle parasites to plant pathogens with potential economical value (Table 
4.3). Among these, HRG-1 orthologs of human (hHRG-1), three trypanosomatids 
Leishmania amazonesis (LHR-1), Trypanosoma brucei (TbHRG-1) and Trypanosoma 
cruzi (TcHRG-1), two filarial worms Brugia malayi (BmHRG-1) and Dirofilaria 
immitis (DiHRG-1), a hookworm Ancylostoma ceylanicum (AceHRG-1) and a plant 
parasite Meloidogyne incognita (MiHRG-1) were chosen for identifying small 
molecule antagonists (Fig. 4.6). 
Two full primary screens were performed on LHR-1 and MiHRG-1, 
respectively, employing a library of 233,360 chemically distinct small molecules 
assembled by the UT Southwestern Medical Center’s HTS Core facility from 
ChemBridge Corporation, Chemical Diversity Labs, ComGenex, TimTek, Prestwick, 
and the NIH clinical collection.  The compounds in the library satisfy a relaxed set of 
Lipinsky’s rules, with 99% having a molecular weight less than 550 (average 250-
300). Compounds were assayed at 5 µM. At this concentration, 2670 primary LHR-1 
hits (1.1%) and 2773 (1.2%) primary MiHRG-1 hits were identified with a Z score ≥ 
3 (Fig. 4.7). The top 1,500 compounds from the two primary screens with a Z score ≥ 
5 were confirmed and specified by following secondary and counter screens using all 
the HRG-1-related proteins listed in Fig. 4.3 and Fig. 4.6. A more stringent hit rate 
(~0.1%) would be achieved by decreasing compound concentration to 0.5 µM. 










Caenorhabditis elegans None + 
Oscheius tipulae None   
Pristionchus pacificus None   
Brugia malayi Human + 
Wuchereria bancrofti Human + 
Loa loa Human + 
Dirofilaria immitis Dog, rarely human   
Litomosoides sigmodontis Rodents   
Onchocerca volvulus  Human   
Onchocerca ochengi Cattle   
Ancylostoma ceylanicum Human + 
Ancylostoma duodenale  Human   
Ancylostoma caninum  Dog   
Necator americanus  Human   
Heligmosomoides polygyrus Woodmice   
Nippostrongylus brasiliensis  Rat   
Ascaris suum Pig   
Schistosoma japonicum Human   
Schistosoma mansoni Human + 
Strongyloides ratti  Rat   
Trichuris muris  Mice   
Haemonchus contortus Sheep / goat + 
Ostertagia ostertagi  Cattle   
Teladorsagia circumcincta  Sheep / goat   
Parastrongyloides trichosuri  Possum   
Meloidogyne incognita Plant   
Meloidogyne hapla Plant + 
Globodera rostochiensis  Potatoes / tomatoes   
Trichinella spiralis Human, rat, pig   
Trichostrongylus colubriformis  Human, cattle   
Cooperia oncophora Cattle   
Dictyocaulus viviparus  Cattle   
Oesophagostomum dentatum  Pig   
Leishmania amazonensis  Human   




Figure 4.6. Standard yeast growth curves of parasitic HRG-1 paralogs. Yeast 
cells expressing hHRG-1, LHR-1, AceHRG-1, BmHRG-1, DiHRG-1 or MiHRG-1 
were grown to stationary phase. Yeast were plated at OD600 = 0.05 in growth medium 
(70 µl/well; 384 wells/plate) containing increasing concentrations of GaPPIX. The 
assay plates were then incubated without shaking in a humidity container at 30ºC. 
OD600 values were measured over 48 hr.  All samples contained 1% DMSO, except “-









Figure 4.7. Summary of HTS screen results. (A) 233,360 compounds were assayed 
for rescue of LHR-1 yeast growth in the presence of 10µM GaPPIX. Each dot (black) 
represents the OD600 value of an individual well incubated with compound for 36 hr. 
The cutoff for a “primary hit” (Z score ≥ 3) is indicated by the orange dashed line. 
Negative (1% DMSO; green) and positive (0.2% glucose; red) control wells are 









against different HRG-1-related proteins, validated by LC/MS, and used to generate 
dose response curves (Fig. 4.8).  
 
Validation of C. elegans HRG-1 paralog antagonists 
Even though the original screen was conducted against LHR-1, the top 
compounds were rescreened using all the HRG-1-related proteins expressed in the 
yeast assay.  To translate our results from a yeast HTS assay to an in vivo 
physiological model, we chose to evaluate the efficacy of lead antagonists against the 
C. elegans heme transporters.  Two compounds that have CeHRG-4 inhibitor activity 
(#1 and #2) were further validated in C. elegans. Consistent with the initial assays, 
compound #1 was found to be an antagonist of both CeHRG-4 (AC50 = 0.69 ±0.11 
µM) and hHRG-1 (AC50 = 1.89 ±0.23 µM), whereas #2 was remarkably selective for 
CeHRG-4 (AC50 = 0.54 ± 0.16 µM) over hHRG-1 (no activity detected) (Fig. 4.8A). 
Since the expression of the heme transporters are driven by the GAL1 promoter, false 
positive hits that mimic glucose suppression of CeHRG-4 expression may be 
obtained. To rule out this potential artifact, yeast integrated with HA-tagged CeHRG-
4 (CeHRG-4-HA) was used to evaluate protein levels by immunoblotting. As shown 
in Fig. 4.8B, neither of the two compounds altered CeHRG-4-HA protein levels.   
The two compounds were then subjected to verification of their activity in C. 
elegans. We first examined their activity in our previously established heme sensor 
strain, a transgenic worm that stably expressed a Phrg-1::gfp (IQ6011 strain) 




at low heme but GFP expression is suppressed by heme (Fig. 4.9A). Knockdown of 
hrg-4 or hrg-1 result in derepression of GFP expression in IQ6011 even in the 
presence of sufficient heme, providing us the basis for evaluating the effects of 
pharmacological blocking of heme uptake in worms [58,145]. Growing IQ6011 at 
20µM heme supplemented with DMSO showed no GFP fluorescence. By contrast, 
growing at 20µM heme supplemented with either 100µM compound #1 or #2 
significantly turned on GFP expression (Fig. 4.9B). This result indicates that both of 
the two compounds can block heme uptake in C. elegans, thus activating a heme 
depletion signal from the hrg-1 promoter. To demonstrate that this GFP upregulation 
is not an artifact we used a different reporter strain, Pvha-6::gfp. vha-6 is an 
intestinally expressed, non-heme responsive gene [173]. Consistent with previous 
results, 100µM compound #1 or 10µM compound #2 significantly upregulated GFP 
in IQ6011 strain in the presence of 10µM heme but not in the Pvha6::gfp strain (Fig. 
4.10), indicating that the upregulation of GFP in IQ6011 strains was not due to a non-
specific effect of the compound on the GFP reporter. 
C. elegans requires heme for growth and reproduction. Worms respond in a 
biphasic manner to heme levels in liquid axenic mCeHR medium [15]. The optimal 
concentration for worm growth is 20μM heme. We next examined whether the 
inhibitors block heme uptake, and therefore interfere with worm growth and 
reproduction. IQ6011 strain growing at 10µM heme lay broods of more than 50 
progeny, which was reduced to 1~2 progeny at 6µM heme. Growth of the worms was 
fully arrested below 4µM heme. Adding 1% DMSO vehicle had a modest effect on 




Figure 4.8. Dose responsive analysis on resupplied compounds. (A) Two primary 
CeHRG-4 hits were repurchased, validated by LC/MS, and assayed at multiple 
concentrations (0.003-30 µM) in triplicate. (B) A yeast strain expressing HA-tagged 
CeHRG-4 was used to evaluate compound effects on HRG-1-related protein 
expression. Cells were cultured with no GaPPIX (-Ga), or 1 µM GaPPIX with 30 µM 







Figure 4.9. Compound hits upregulate GFP expression in heme sensor strain. 
Synchronized Phrg-1::gfp (IQ6011) worms were put in mCeHR2 medium at L1 
stage, 100 worms/well in 24-well plates. Worms were grown in the presence of either 
(A) indicated amounts of heme, or (B) 20µM heme supplemented with 1% DMSO, 










Figure 4.10. Compound hits block heme uptake in a dose-responsive pattern in 
worms. Synchronized (A) Phrg-1::gfp (IQ6011) or (B) Pvha-6::gfp worms were put 
in mCeHR2 medium at L1 stage, 100 worms/well in 24-well plates. Worms were 
grown in the presence of 10µM, 30µM or 100µM compounds (from 10mM DMSO 
stock) or corresponding concentration of DMSO alone for 4 days. GFP fluorescence 
intensities were quantified by COPAS BioSort. The settings for GFP measurement 

















































































Figure 4.11. Compound hits interfere with heme dependent worm growth. 100 
larvae at the L1 stage were grown in mCeHR2 medium for 9 days in a 24-well plate 
with each well containing an increased concentration of heme or 10µM heme with 
supplemented with 1% DMSO, 30µM GaPPIX or 100µM compounds (from 10mM 
DMSO stock). The total numbers of worms in each well were counted on day 9. Each 
data point represents the mean (± SEM) from experiments performed in duplicate, 













































100µM compound #1 and #2 fully arrested worm growth (Fig. 4.11). This 
observation provides further evidence of the inhibitory activity of the compounds on 
C. elegans HRG-1 paralogs. 
 
Discussion 
Parasitic worm infections are a huge burden to public health since more than 
two billion people world-wide are afflicted by helminthic infections. Annual crop 
losses due to plant-parasitic nematodes are estimated to be around eighty billion 
dollars [122,123]. There is an urgent need to find new drug targets to tackle 
helminthic infections because drug resistance is already prevalent in these parasites 
[124]. We previously showed that parasitic nematodes lack the ability to make heme 
and rely on exogenous heme for their growth and development [15]. A recent study 
has demonstrated that the infectivity of hookworms, which feed on blood in the host, 
was significantly lower in hamsters fed a low-iron diet [125]. This observation 
revealed the importance of host heme and iron status in the survival of parasitic 
nematodes. Interestingly, protozoan parasites such as Trypanosomes, the causative 
agents of diseases such as sleeping sickness (Trypanosoma brucei), Chagas disease 
(Trypanosoma cruzi) and leishmaniasis (Leishmania major), also seem to lack the 
ability to make heme and therefore utilize exogenous heme [13,14,174].  
Using the heme auxotroph C. elegans, we have discovered CeHRG-1 and 
CeHRG-4, the first eukaryotic heme importers/ transporters. We further demonstrated 




suggesting they could potentially be used as novel drug targets against parasitic 
infections or heme/iron homeostasis disorders [120,152]. The assay strategy to 
identify HRG1-related protein antagonists exploits the observation that ectopic HRG-
1-related protein expression confers uptake of heme, and heme analogs in yeast. A 
simple growth assay was developed in which yeast expressing HRG1-related protein 
are grown in the presence of the toxic heme analog GaPPIX. Antagonists that prevent 
heme uptake via HRG1-related proteins would be identified by their ability to 
suppress GaPPIX cytotoxicity as measured by yeast growth using optical absorbance. 
The gain-of-function phenotype (yeast viability rather death) limited the number of 
potential false-positive hits. 
We successfully optimized conditions of the growth assay to a HTS-
compatible format and validated it on a robust statistical basis. This assay was then 
applied to a screen of 233,360 structurally diverse small molecules, aimed at the 
identification of heme transport modulator compounds. Primary screening was 
performed on yeast expressing LHR-1 or MiHRG-1 in a 384-well plate format, 
followed by secondary screening of active compounds using eight HRG-1-related 
proteins and four C. elegans HRG-1 paralogs as targets. On average, ~1% of the 
compounds were identified as hits from primary screens, featuring a Z score of ≥ 5, 
none of which had previously been identified as drug candidates. Ninety-one 
compounds representing different groups of HRG-1-related protein antagonists were 
repurchased, validated by LC/MS, and used to generate dose-response curves. As a 
proof-of-principle, two compounds that have CeHRG-4 antagonist activity were 




intensity in the IQ6011 heme sensor strain. Addition of these compounds also inhibits 
heme dependent growth of C. elegans in liquid axenic medium. These results 
demonstrate that the HTS of small molecule libraries against HRG1-related protein in 
a rapid and simple 384-well plate format assay was able to identify novel heme 
transport modulators as anti-parasitic compounds or biological tools to study heme 
homeostasis. 
Published reports have suggested a role for heme in the pathogenicity of 
various parasitic worms. Hookworm infection due to Ancylostoma ceylanicum is 
prevalent in developing countries and is associated with iron deficiency anemia. 
Hamsters fed a diet with reduced iron had a significant reduction in the intestinal load 
of worms. Hookworms, like C. elegans, also lack the ability to make heme; it is thus 
plausible that animals fed a low-iron diet have reduced worm burden due to 
inadequate amounts of heme for hookworm metabolism [125]. Filarial nematodes, 
such as Brugia malayi and Dirofilaria immitis are the causative agents of severe 
filariasis infections including elephantiasis. Analysis of the genome sequence of 
Brugia malayi revealed the absence of the heme biosynthesis enzymes in these 
parasites [126]. Therefore, it is highly likely that these parasites obtain heme from the 
host or from Wolbachia, an intracellular endosymbiotic bacterium that has a 
functional heme biosynthesis pathway [127]. Antibiotics that eliminate the 
endosymbiont have inhibitory effects on the development and fertility of the parasitic 
nematode and have been used to treat patients with filariasis. Recent studies on 
Leishmania and Trypanosoma have also reported that proliferation of these protozoa 




PdMPIX inhibited T. cruzi proliferation, and this inhibition could be reverted by the 
presence of heme [118]. Since heme is important for the growth and development of 
these parasites, our small molecule antagonist screen targeting heme transporters 





Chapter 5:  Conclusions and future directions 
 
Conclusions 
Our long term objectives are to identify the mechanisms for heme homeostasis 
in eukaryotes and develop anti-parasitic therapeutics that target the parasites’ heme 
transport system. Utilizing the heme auxotroph C. elegans, we have previously 
identified bona fide heme transporters, CeHRG-1 and CeHRG-4. During the past few 
years, we performed extensive functional analysis using yeast and worm as model 
systems, to investigate the mechanism of heme transport and intracellular trafficking 
by HRG-1-related proteins. This work laid the groundwork for the subsequent 
discovery of HRG-1 homologs in parasites and for developing a high-throughput 
screen for antagonists against HRG-1 homologs. The major findings in this study are 
listed and discussed below: 
1) Single knockout of either hrg-1 or hrg-4 showed no obvious phenotypes in C. 
elegans. Only the Δhrg-1Δhrg-4 double mutant worms exhibited a modest growth 
delay at low heme, which could be fully rescued with excess heme. These results 
imply that worms have redundant mechanisms for heme uptake and transport.  Indeed, 
C. elegans has two additional HRG-1 paralogs, CeHRG-5 and CeHRG-6, which are 
legitimate heme transporters as assessed in the yeast functional assays. 
2) Yeast does not have a robust heme uptake system. The hem1Δ yeast strain, 




function of HRG-1-related proteins. Ectopic expression of HRG-1-related proteins in 
the hem1Δ strain revealed heme import activity, validating the use of the yeast as a 
heterologous system for heme transport study. 
3) CeHRG-1 and CeHRG-4 share only 27% identity and have different 
subcellular localizations. However, sequence analysis revealed topologically 
conserved residues. Functional analyses in yeast showed that CeHRG-1 requires both 
a specific histidine (H90) in the predicted second transmembrane domain (TMD2) 
and the FARKY motif in the C-terminus tail for heme transport. By contrast, the 
plasma membrane CeHRG-4 transports heme by utilizing a histidine in the 
exoplasmic (E2) loop (H108) and the FARKY motif. Optimal activity in heme 
limiting conditions requires a histidine in the E2 loop of CeHRG-1 (H135) and 
tyrosine in TMD2 of CeHRG-4 (Y63).  
4) Expression of CeHRG-1 H90A mutant in the Δhrg-1Δhrg-4 worms showed an 
unexpected dominant-negative phenotype only at low heme. We speculate that this 
result may be due to aberrant hetero-multimerization or disruption of protein-protein 
interactions between HRG-1 paralogs.  
5) hHRG-1 is only ≈20% identical to CeHRG-1. Mutation of the synonymous 
histidine (H56) in TMD2 of hHRG-1, corresponding to H90 in CeHRG-1, eliminates 
heme transport activity, implying an evolutionary conserved heme transport 
mechanism. Single-nucleotide polymorphisms in hHRG-1 are present in humans.  
Two such variants, P36L and W115C, show significantly reduced heme transport 




6) FLVCR2 was recently reported as a heme importer in mammalian cells. 
However, FLVCR2 did not rescue heme-dependent growth of hem1Δ yeast strain, 
indicating it may be actually a heme exporter as its paralog, FLVCR1.  
7) Ectopic expression in mammalian cells showed CeHRG-4 localized to the 
plasma membrane, whereas CeHRG-1 and hHRG-1 co-localized with endosomal and 
lysosomal markers. Worm and human HRG-1 have a conserved but sub-optimal 
tyrosine (YxxxØ in humans and YxxØ in worms) and an acidic-dileucine (DxxIL in 
humans and ExxxLL in worms) based sorting motifs at their C-terminal domains, 
which are absent in CeHRG-4. Swapping the C-terminal domains of HRG-1-related 
proteins resulted in an equivalent exchange in their subcellular localization. By 
contrast, switching the N-terminal domains or TMDs did not affect protein 
localization. These results reinforce the possibility that C-terminal domains of HRG-
1-related proteins are required for proper intracellular trafficking. 
8) The N-terminal domain chimeras of worm and human HRG-1 showed 
impaired heme transport activity in yeast. Swapping the N-terminal domains of 
CeHRG-1 and CeHRG-4 switched the protein multimerization profile. These 
observations indicate HRG-1-related proteins have a defined oligomerization pattern 
that is dependent on its respective N-terminal segment.  Furthermore, multimerization 
may play a role in heme transport.  
9) Expression of HRG-1-related proteins dramatically increase yeast sensitivity 
to the toxic heme analog, GaPPIX. A high-throughput screen aimed at identifying 




10) A high-throughput screen employing a library of 233,360 small molecule 
compounds was performed to discover inhibitors of HRG-1 homologs from humans, 
helminths and Trypanosomatids. About 1% of the library qualified as primary 
antagonists with the ability to inhibit transport activity of at least one heme 
transporter. Ninety-one compounds representing different categories were 
repurchased and subjected to dose-responsive analysis in yeast.  
11) Two leading compounds identified as antagonists of CeHRG-4 were validated 
in in vivo assays using C. elegans. Both of the compounds specifically increased GFP 
signal in the “heme sensor” IQ6011 strain and inhibited heme-dependent growth of 
worms  
 
Significance and speculations  
Trypanosomatids and helminths are unable to synthesize heme de novo, 
although they need heme to sustain their growth and reproduction. Our group 
previously discovered CeHRG-1 and CeHRG-4 as the first bona fide eukaryotic heme 
importers/transporters [58]. In silico analysis revealed topologically conserved amino 
acids as potential heme ligands in HRG-1-related proteins. In this dissertation, we 
dissected the significance of these residues in HRG-1 function as heme transporters 
using the hem1Δ yeast strain. Our results revealed HRG-1-related proteins transport 
heme across membranes through the coordinated actions of these topologically 




mechanism for heme import employed by HRG-1-related proteins is ancient and 
predates vertebrate origins.  
Our assays in C. elegans suggest that worms have redundant mechanisms for 
heme uptake and transport. We showed that in addition to CeHRG-1 and CeHRG-4, 
two additional HRG-1 paralogs exist in worms; CeHRG-5 and CeHRG-6 are capable 
of heme transport in yeast. It is unclear why expressing the CeHRG-1 H90A mutant 
in worms causes a dominant-negative phenotype. One possibility is that HRG-1 
paralogs may oligomerize as homo- and/or hetero- multimers to transport heme in C. 
elegans.  If true, the physiological consequence of this would be far-reaching for a 
soil nematode that is a heme auxotroph.  It would provide the worm with a 
competitive advantage in the rhizosphere by maximizing heme uptake in different 
environmental and nutrient conditions.  Further study on the regulation and 
interaction of worm HRG-1 paralogs will lead to a deeper understanding of the 
mechanism of HRG-1-related proteins in organismal heme homeostasis.  
The trafficking studies in mammalian cell lines revealed the proper topology 
of HRG-1-related proteins and provide the first description for how HRG-1 
trafficking may be regulated in worms and humans. Assays using HRG-1 chimera 
mutants demonstrate that the N-terminal and C-terminal domains of HRG-1-related 
proteins are important for their function and localization, respectively. The N-
terminal domains may be involved in the multimerization process of HRG-1-related 
proteins, whereas the C-terminal domains possibly direct their intracellular trafficking 




Currently, there are no pharmacological means to aid in the study of the 
cellular and physiological roles of eukaryotic heme transporters. We, for the first 
time, developed a high-throughput screen and identified potential antagonists of 
HRG-1-related proteins. This HTS strategy can be used to screen inhibitors targeting 
heme transporters in a labor and cost effective manner. The lead compounds 
identified in this screen will be invaluable biological tools to study the mechanism of 
eukaryotic heme transport. Subsequent study in parasites will provide novel drug 
candidates for treatment in helminths that infect humans, livestock, and plants, as 
well as in humans with genetic disorders of heme and iron metabolism. 
 
Future directions 
In vivo analysis of worm HRG-1 paralogs  
While detailed studies have been conducted to characterize the function of 
CeHRG-1 and CeHRG-4 in mediating heme homeostasis, not much is known about 
the role of CeHRG-5 and CeHRG-6. We postulate that, since worms rely solely on 
exogenous heme for their growth and development, they have additional mechanisms 
for heme acquisition that might include CeHRG-5 and CeHRG-6. Therefore, spatial 
and temporal expression patterns, along with the intracellular location need to be 
determined for CeHRG-5 and CeHRG-6. We have identified a cis element, termed 
HEme-Responsive Element (HERE), in the promoter region of hrg-1, which is 
responsible for its heme-dependent transcriptional regulation [145]. However, this 




paralogs. Instead, the 3’ UTR might be important for the regulation of hrg-4. While 
worms expressing hrg-4::yfp with hrg-4 3’ UTR had YFP expression, there was no 
fluorescence in the worms expressing hrg-4::yfp with unc-54 3’ UTR (unpublished 
observations). It has been shown before that 3’ UTRs are important for the 
downregulation of mRNA levels [175].  
By contrast, the expression levels of hrg-5 and hrg-6 mRNAs are not 
responsive to heme. Interestingly, while cloning hrg-5, we observed that there were 
discrepancies between the genomic DNA and the cDNA sequences. Further studies 
conducted on hrg-5 in worms suggest that this gene might undergo editing at the 
RNA level (unpublished observations). Investigating the effects of heme on hrg-5 
editing and analyzing hrg-5 genomic DNA and mRNA in the C. elegans ADAR 
mutants (ADAR encodes the enzyme responsible for RNA editing by converting 
adenosines to inosines) will provide a better understanding of the posttranscriptional 
control of hrg-5 [176]. The hrg-6 gene, on the other hand, shares its promoter region 
with hrg-4 on an opposite orientation. A graduate student in the lab, Haifa Bensaidan, 
has been conducting studies to determine whether hrg-6 is regulated via hrg-4 
expression and promoter competition (unpublished observations).  
These findings reveal the possibility of a complex regulatory circuit involving 
the regulation of hrg-1 paralogs in C. elegans. The differences in regulation of 
individual hrg-1 genes could provide molecular insights into their functional aspects 
and individual contribution to heme homeostasis within the intact animal.  




As mentioned above, we have identified topologically conserved residues in 
the worm and human HRG-1 proteins despite only ≈20% amino acid identity.  
Although it is expected that worms need heme transporters, why do humans need 
HRG-1 when vertebrates make their own heme? It has been shown that some of the 
heme released within the macrophages after phagocytosis of senescent RBCs can be 
exported by FLVCR1 [63].  Carine White, a post-doctoral fellow in the Hamza lab 
has investigated the expression, regulation, intracellular trafficking, and activity of 
hHRG-1 in macrophages during erythrophagocytosis (EP). Her data reveal that the 
expression of hHRG-1 is upregulated during EP and the protein localizes to the 
phagolysosomal membranes which surround the engulfed RBCs.  Depletion of Hrg-1 
by siRNA in mouse bone marrow macrophages results in significant reduction of 
heme transport from the phagolysosomal compartment into the cytoplasm.  In 
addition, the hHRG-1 P36L variant has impaired heme transport activity as 
determined by experiments in zebrafish and macrophages confirming our results in 
yeast (unpublished observations). Further studies to determine whether genetic 
lesions in hHRG-1 cause unexplained anemia or iron accumulation in the 
reticuloendothelial system of humans are underway and could provide functional 
insights into the role of hHRG-1 in heme transport in mammals. 
 
Structure-function analysis of HRG-1 proteins  
The domain-swapping experiments revealed that the C-terminal domains of 
HRG-1-related proteins are important for their localization. Specifically, the tyrosine 




HRG-1 to endo-lysosomal compartments. Interestingly, hHRG-1 has an suboptimal 
tyrosine based (YxxxØ) and di-leucine based (DxxIL) sorting motifs. This provides a 
possible explanation to the observation that, instead of basolateral localization, 
hHRG-1 was detected in vesicles beneath the apical plasma membrane in polarized 
MDCK II cells.  It is plausible that the two imperfect motifs might not be strong 
enough to direct basolateral membrane trafficking in polarized cells.  However, in 
non-polarized cells such as the macrophage, these motifs permit hHRG-1 to be 
retrieved from the plasma membrane via the DxxIL motif and localize to the endo-
lysosomal compartments directed by the YxxxØ motif. Point mutations of these 
sorting motifs have been generated to either abolish them altogether or to make them 
into a strong canonical motif to explore and the trafficking of hHRG-1 in both 
polarized and non-polarized cells. 
HRG-1-related proteins migrate as multimers on SDS-PAGE gels. 
Preliminary crystallography studies performed by our collaborator, Dr. Daniel 
Rosenbaum at UTSW, reveal that HRG-1 proteins from six different species form 
similar, large multimeric complexes equivalent to about 10 protomers (unpublished 
observations). We showed that the N-terminal domains are important for the function 
of HRG-1-related proteins, possibly by affecting the multimeric state. It will be 
interesting to analyze the crystal structures of these N-terminal mutant proteins. 
Furthermore, fluorescence resonance energy transfer (FRET) techniques could be 
applied to assess whether HRG-1-related proteins physically interact with each other 





Identification of interacting partners  
Heme uptake and transport in bacteria have been shown to involve complex 
molecular networks. Hence, we speculate that the HRG-1-related proteins might also 
be a part of an elaborate network of molecules regulating heme uptake, transport and 
storage. The RNAi screen of trafficking factors in the strain IQ6111 has identified a 
number of regulators of secretion and endocytosis that altered CeHRG-1 stability or 
localization in worms. Celine Vanhee, a post-doctoral fellow, is currently working on 
identifying interacting proteins that coimmunoprecipitate with HRG-1 in worms and 
mammalian cells using multidimensional protein identification technology (MudPIT). 
Furthermore, transcriptional profiling experiments of the hrg-1 and hrg-4 deletion 
worms grown under different heme concentrations might identify genes that are 
dysregulated due to disruption in heme homeostasis.  
 
Discover potent and selective HRG-1 antagonists  
  
We have developed and executed a high-throughput screen of 233,360 
compounds for HRG-1 antagonists in a heterologous assay in yeast, and validated 
several leads from this screen in worms. The lead compounds will be further analyzed 
in our functional downstream assays. We will assess the efficacy, selectivity, and 
chemical liabilities (metabolism, cell permeability, toxicity) of these compounds in 
yeast, worms, mammalian cells and zebrafish, to ultimately develop the compounds 







Appendix I. Yeast strains used in this study 
Strain name Genetic 
background 
Relevant genotype Source 
DY1457 W303 W303 MAT_ ura3-52 leu2-3,112 trp1-1 his3-11 ade6 
can1-100 
 
 DY1457 hem1::LEU2 trp1-1 his3-11 ura3-52 can1-100  
YPH499  MATa ura3-52 lys2-801(amber) ade2-101(ocher)  
trp1-63 his3-200 leu2-1 
 
OPY102 YPH499 hem1::KanMX fre1::LEU2 fre2::HIS3  
 YPH499 hem1::KanMX fre1::LEU2 fre2::HIS3 trp1-
63::TRP1 pMET3-FRE1 
This study 
CeHRG-4 DY1457  his3-11::HIS3 pGAL1-CeHRG-4 This study
CeHRG-4-HA DY1457  his3-11::HIS3 pGAL1-CeHRG-4-HA This study
yhHRG-1 DY1457  his3-11::HIS3 pGAL1-yhHRG-1  This study
CeHRG-414 DY1457  his3-11::HIS3 pGAL1-CeHRG-414 This study
CeHRG-5 DY1457  his3-11::HIS3 pGAL1-CeHRG-5 This study
CeHRG-6 DY1457  his3-11::HIS3 pGAL1-CeHRG-6 This study
yLHR-1 DY1457  his3-11::HIS3 pGAL1-yLHR-1  This study
yTbHRG-1 DY1457  his3-11::HIS3 pGAL1-yTbHRG-1  This study
yTcHRG-1 DY1457  his3-11::HIS3 pGAL1-yTcHRG-1  This study
yAceHRG-1 DY1457  his3-11::HIS3 pGAL1-yAceHRG-1  This study
yBmHRG-1 DY1457  his3-11::HIS3 pGAL1-yBmHRG-1  This study
yDiHRG-1 DY1457  his3-11::HIS3 pGAL1-yDiHRG-1  This study






Appendix II. Oligonucleotides used in this study 
































Appendix III. Genotyping of HRG-1-related deletion worms. 
 (A) Left: PCR analysis of genomic DNA obtained from wild-type N2 worms (lanes 1 
and 3) and homozygous mutants. hrg-1 specific primers were used in lanes 1 and 2; 
hrg-4 primers were used for lanes 3 and 4. Right: PCR screening of cDNA 
synthesized from total RNA isolated from wild-type N2 worms and homozygous 
mutants. The hrg-1 primers were used for lanes 1 and 2; hrg-4 primers were used for 
lanes 3 and 4. (B) DNA sequence for Δhrg-4 (tm2994) along with predicted amino 
acid sequence of the RT-PCR product. The boxed region indicates the new sequences 
that are added. 
(Abbhirami Rajagopal and Xiaojing Yuan conducted the experiment.) 









Appendix IV. Summary of HRG-1-related proteins intracellular localization. 
Gene 
Localization in HEK293 
cells 
Localization in MDCKII cells 
CeHRG-1 Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-4 Plasma membrane Apical surface 
hHRG-1 Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-114 Plasma membrane Apical surface 
CeHRG-441 Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-144 Plasma membrane Apical surface 
CeHRG-411 Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-141 Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-414 Plasma membrane Apical surface 
CeHRG-1ΔN Endosomal / lysosomal Vesicles underneath the apical surface 
CeHRG-4ΔN Plasma membrane Apical surface 
hHRG-11-Ce4 Plasma membrane Apical surface 
CeHRG-44-h1 Endosomal / lysosomal Vesicles underneath the apical surface 
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